

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization  
International Bureau



(43) International Publication Date  
22 February 2001 (22.02.2001)

PCT

(10) International Publication Number  
WO 01/12216 A1

- (51) International Patent Classification<sup>7</sup>: A61K 39/00, C12N 15/56, 9/10, 15/00, 5/06 (74) Agent: FARRELL, Kevin, M.; P.O. Box 999, York Harbor, ME 03911 (US).
- (21) International Application Number: PCT/US00/22121 (81) Designated States (*national*): AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW.
- (22) International Filing Date: 14 August 2000 (14.08.2000)
- (25) Filing Language: English
- (26) Publication Language: English
- (30) Priority Data:  
09/374,721 13 August 1999 (13.08.1999) US (84) Designated States (*regional*): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).
- (71) Applicant: PROTEINIX COMPANY [US/US]; 16020 Industrial Drive, Gaithersburg, MD 20877 (US).
- (72) Inventors: KENTEN, John, Henry; 21021 Sugar Ridge Terrace, Boyds, MD 20841 (US). ROBERTS, Steven; 8808 Melwood Road, Bethesda, MD 20817 (US). LOHNAS, Gerald; 13129 Manor Drive, Mt. Airey, MD 21771 (US).

**Published:**

— With international search report.

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.



WO 01/12216 A1

(54) Title: HEAT SHOCK FUSION-BASED VACCINE SYSTEM

(57) Abstract: Disclosed are self-epitope-containing heat shock fusion proteins, DNA constructs encoding such fusion proteins, and methods of use. More specifically, disclosed are ubiquitin fusion proteins comprising ubiquitin fused to a plurality of identical or non-identical self-epitopes at specified locations. Immunization of an animal with these ubiquitin fusion proteins elicits an immune response to self-antigens present on endogenous proteins. Generation of an immune response to a specified self-antigen is a mechanism to decrease the levels of the endogenous protein below base-line.

HEAT SHOCK FUSION-BASED VACCINE SYSTEMBackground of the Invention

The construction of immunogenic peptides or peptide conjugates is an active and ongoing research pursuit. The goals include production of reagent antibodies for research, for example in neurobiology, and production of synthetic vaccines for human or veterinary application. Small synthetic peptides are poor antigens and typically require covalent association with macromolecular carriers and administration with adjuvant in order to elicit an immune response. Carriers also provide T-cell epitopes necessary for cell-mediated response and for helper functions in the humoral response. When presented appropriately, synthetic peptides can elicit antibodies against large proteins which display the same peptide epitope within their sequence. Vaccine research further seeks to define those synthetic immunogens capable of inducing an antibody response that is also able to neutralize the infectious activity of a virus or other pathogen from which the protein is derived.

A significant effort has been devoted to discovery of general rules which govern the selection of protein epitopes by the immune system and development of methodology for mimicry of such epitopes with synthetic immunogens. Evidence has emerged suggesting that linear or discontinuous epitopes may be recognized and that these may adopt defined conformational states that are not readily duplicated in a synthetic peptide. Attempts to devise conformationally restricted peptides as superior antigens have also been given serious attention. In such approaches the structural context of a peptide sequence within a protein antigen is considered in producing a suitable mimic. Typically, the epitope may adopt a secondary structure such as a  $\beta$ -turn or  $\alpha$ -helix. A similar structure may be induced in a small peptide by intramolecular covalent modification between two residues that constrains its conformational freedom. These ordered structures can be important as B-cell

-2-

determinants. However, they are insufficient immunogens in the absence of helper T-cell determinants. Recently developed peptide vaccine models have incorporated T-cell epitopes in association with the B-cell epitope. Designs  
5 include simple tandem linear synthesis of peptides as well as increased epitope valency through coupling T-cell and B-cell peptides to a branched polylysine oligomer. The latter assemblies, referred to as multiple antigenic peptides, have shown promise as vaccines against various  
10 pathogens.

Unlike the conformationally defined B-cell epitopes, sequences recognized by T-cells undergo extensive processing to short linear peptide fragments before they are bound to a major histocompatibility complex (MHC) for  
15 recognition at the surface of an antigen-presenting cell. This elaborate processing mechanism depends on intracellular proteolytic activity and translocation of the products to the cell membrane. Synthetic peptide immunogens may not effectively participate in this  
20 process, despite the presence of the T-cell epitope. The immunogenicity of the molecule can be expected to correlate with the efficiency of natural processing of the T-cell epitope. Studies with linear synthetic peptides indicated that chimeric peptides containing T-  
25 cell and B-cell epitopes were superior immunogens when the B-cell epitope was amino-terminal. However, the reverse orientation has also been reported to produce a stronger immune response. A general rule may not be obvious since natural antigen processing probably accepts  
30 various orientations, including internal epitopes that require multiple processing steps to release the peptide. Also the efficiency of a construct may depend on many other factors, such as molecular context and flanking sequences that affect processing or presentation and the  
35 overall nature of the immunogen which can affect the functional pairing between several available T-cell and B-cell epitopes.

-3-

Further limitations to the use of synthetic peptides as vaccines result from the genetic restriction to T-cell helper function. Multiple MHC class II molecules encoded within the genome of a species are subject to allelic exclusion. A specific T-cell epitope may interact with only one or a few alleles of the MHC. Therefore individuals may respond differently to the immunogen despite inclusion of T-cell helper epitopes. Vaccine development must overcome the MHC-restricted response to provide the broadest possible response in an outbred population. In the murine model the T-helper cell responses are MHC-restricted and major haplotypes H-2b, H-2k, and H-2d are represented in several inbred strains. Certain T-cell epitopes are known to be recognized in the context of multiple MHC class II alleles and can thereby provide "promiscuous" T-helper stimulation. A number of epitopes, such as from tetanus toxin, measles virus, and Mycobacterium tuberculosis have been reported to be universally immunogenic. These may have significant benefit for subunit vaccine design.

As an alternative to chemical synthesis, molecular biological techniques can provide significant advantages for production of polypeptides that display both B-cell and T-cell epitopes. Expression of proteins from cloned genes obviates burdensome peptide synthesis, purification and conjugation chemistry typically used in production of immunogenic materials. Furthermore, the stochastic chemistry for preparation of peptide-carrier conjugates is replaced by the defined chemical structure provided by the genetic fusion. Therefore the epitopes can be introduced in ordered structures that have optimal and reproducible immunogenic properties. Considerations that arise in the development of optimal designs can be addressed at the genetic level. Thus, definition of the target epitopes and their flanking sequences, relative orientation and conformations of these sequences within the larger polypeptide, and epitope copy frequency can be established in the gene design.

-4-

Several recombinant host proteins have been successfully utilized for immune presentation of peptide epitopes. The *E. coli* maltose-binding protein (MalE) has been used to study the influence of location and orientation of inserted T-cell epitopes. The major coat protein (pVIII) of filamentous bacteriophage fd has been used for display of HIV B-cell epitopes at the N-terminus. The recombinant phage particles evoked a strong antibody response in mice, which cross-reacted with HIV strains and which is also capable of neutralizing the virus. These approaches promise to enhance the potential of subunit or synthetic vaccine models.

#### Summary of the Invention

The present invention relates to a variety of self-epitope-containing heat shock fusion proteins. In one embodiment, the heat shock protein ubiquitin is fused to a variety of self-epitopes or epitope-containing segments. The specific fusion architecture is described in detail below. The epitope-containing segments of the ubiquitin fusion protein comprise either a single self-epitope or a group of identical or non-identical self-epitopes.

The present invention also relates to DNA constructs which encode a self-epitope-containing heat shock fusion protein of the type described above, and to cells transformed with such expression constructs.

In other aspects, the present invention relates to methods for stimulating an immune response in an animal, the immune response being directed toward a self-antigen. The self-epitope containing heat shock fusion protein is administered to an animal under conditions appropriate for the stimulation of an immune response. In an alternative embodiment, a DNA construct encoding the self-epitope containing heat shock fusion protein is introduced into cells, rather than the fusion protein directly.

-5-

The present invention also relates to methods for inducing the production of antibodies to endogenous biomolecules using a heat shock fusion protein as described above where the said peptide epitopes are, or  
5 are not, related to the endogenous biomolecules in chemical composition but are so called "mimics" of the biomolecular structure and as such have the ability to elicit antibodies to the said biomolecules. Such peptide (epitope) mimics are isolated typically by using  
10 phage peptide libraries.

The present invention also relates to methods for reducing levels of a predetermined endogenous protein (e.g., hormone(s)) in an animal relative to base-line levels, to methods for reducing endogenous TNF levels  
15 relative to those in a disease state, to methods for reducing the sperm count in males or inactivating sperm in men and women, to methods for reducing the allergic response, to methods for increasing the growth rate of an animal and to methods for the production and  
20 identification of antibodies for use in experimental or diagnostic samples.

#### Detailed Description of the Invention

The present invention is based, in one aspect, on the discovery that a fusion protein comprising a heat  
25 shock protein (e.g., ubiquitin), fused to an epitope or epitopes in a defined manner, is useful for the stimulation of a highly specific immune response when administered to an animal. The specific fusion architecture encompassed by the invention will be  
30 discussed in greater detail below.

Heat shock proteins are proteins which are induced during a heat shock. Other stress stimuli are also known to induce a similar response. These proteins are produced to enable the cell to better stand the heat  
35 shock or stress. Under these conditions the pattern of gene expression changes and cells overproduce a characteristic set of proteins commonly referred to as

-6-

heat-shock proteins (hsps). One factor in the induction of the heat shock response is the proteolysis of abnormal proteins.

Various examples of heat shock proteins exist. In yeast, mammals and other eukaryotes, ubiquitin is one of these proteins. Ubiquitin is known to be involved in an ATP-dependent pathway of proteolysis. It is also known that proteolysis is an important step in the production of peptides which function in development of the immune response to antigens. Thus it is recognized that hsps are ideal candidates for use in connection with vaccine development.

In connection with the present invention, ubiquitin is used as a scaffold to stabilize and display recombinant immunologically active heterologous antigens (referred to herein as epitopes), presumably in a form which generally approximates the native conformation of the epitope. This technique is sometimes referred to as conformational mimicry. Generally, the preferred size of the amino acid segments which make up the heterologous antigens ranges from about 5 to about 70 amino acid residues, although larger segments are not intended to be excluded by this statement of the preferred size range.

Ubiquitin is a small 76-residue single domain protein which does not induce an appreciable immune response when administered to an animal. Presumably, this "immunological silence" is based on the fact that ubiquitin is expressed in nearly identical form in all eukaryotic systems. Ubiquitin has a variety of other characteristics which make it an ideal "carrier" for the conformational mimicry approach. For example, ubiquitin is highly resistant to protease digestion and is extremely stable both in vivo and when stored for extended periods of time in vitro. The three-dimensional structure of ubiquitin has been determined by X-ray crystallography and its small size makes it amenable to molecular modeling. Additionally, ubiquitin fusions can be overexpressed in prokaryotic systems such as *E. coli*,

-7-

in soluble form, and purified. One of skill in the art will recognize that for particular applications some of the aforementioned properties are unimportant and dispensable. At the present time, there is no comparable  
5 protein scaffold system available which offer the benefits of the ubiquitin system.

If epitopes are to be fused to the ubiquitin framework as outlined above, whether at a single location or non-contiguous locations, it is important to determine  
10 what types of ubiquitin modifications are tolerated. In this context, "tolerated" can have at least two meanings, systemic tolerance and functional tolerance. It should also be noted that the expression "fused", as used  
15 herein, means covalent bound by an amide linkage. This expression encompasses insertion, as well as substitution. At times, these expressions may be used interchangeably herein.

Systemic tolerance, (i.e., tolerance by the immune system) is important to ensure that the immune response  
20 is directed to the epitopes, and not to the ubiquitin carrier. Thus, epitope insertion should be designed such that changes to the secondary and tertiary structure of ubiquitin are minimized.

Ubiquitin functional tolerance refers to the ability  
25 of the ubiquitin protein to behave functionally in a manner analogous to wild-type ubiquitin. This functional tolerance can also be important in a variety of contexts. This property should also be maintained, at least in connection with certain applications, by the ubiquitin  
30 fusion carrier constructs of the present invention.

As disclosed herein, insertions at particular internal sites in ubiquitin are "tolerated", as this term is defined above. One advantage of using ubiquitin as an immunogenic display scaffold, particularly for an  
35 internally-fused epitope or epitopes, resides in its ability to maintain the secondary structure found in the epitopes native protein. These secondary structures



-8-

include, for example,  $\beta$ -turns and  $\alpha$ -helices. The conformation of the epitope can be further modified by introducing intramolecular bonds between two residues of the epitope which results in conformational constraints on the overall structure of the epitope. The fusion of an epitope or epitopes to terminal regions of ubiquitin also offers advantages in connection with immunostimulatory activities.

In a first embodiment, the present invention relates to a ubiquitin fusion protein comprising ubiquitin fused to a single epitope-containing segment comprising two or more identical or non-identical epitopes, the epitope-containing segments being fused to ubiquitin at fusion sites selected from the group consisting of the N-terminus and an internal fusion site. As discussed in greater detail below, a variety of considerations are taken into account when selecting an epitope of use in connection with the fusion proteins of the present invention. Generally speaking, an epitope which can stimulate an immune response which protects against an infectious disease, an auto-immune disease or allergic reactions are candidate epitopes for use in connection with the present invention. Epitopes which do not fall into one of these categories can also be useful, and non-limiting examples are discussed more fully below.

With respect to the first embodiment, fusions at a single internal location in the ubiquitin moiety must be designed rationally to minimize, for example, adverse consequences with respect to ubiquitin structure and function. In light of the fact that fused epitopes must be "seen" by the immune surveillance system, it is also important that internally fused epitopes are exposed in the folded fusion protein, not buried within a hydrophobic domain. The plurality of epitopes can also be fused to ubiquitin at the N-terminus of the molecule. The epitopes can be identical or non-identical. In addition, the epitopes can be B-cell epitopes, T-cell

-9-

epitopes or a mixture of B- and T-cell epitopes. For many applications, preferred epitopes are B-cell epitopes which are known to be a target for neutralizing antibodies.

5 A second embodiment of the present invention relates to a ubiquitin fusion protein comprising ubiquitin fused to two or more non-contiguous epitope-containing segments, each epitope-containing segment comprising one or more identical or non-identical epitopes. The non-  
10 contiguous locations where fusion is appropriate are internal locations within the ubiquitin moiety, or at the N- or C-terminus of the ubiquitin molecule.

As used herein in connection with the second embodiment, the term "epitope-containing segment" refers  
15 to a sequence of amino acids containing one or more epitopes. The epitopes within any particular epitope-containing segment can be identical, or non-identical. In addition, the epitopes in a particular epitope-containing segment can be B-cell epitopes, T-cell  
20 epitopes or a mixture of B and T-cell epitopes. As discussed above, B-cell epitopes targeted by neutralizing antibodies are preferred in some contexts.

When considering the insertion of epitopes within the ubiquitin molecule, the structure of the ubiquitin  
25 molecule must be considered. The prominent structural features of ubiquitin, as determined by X-ray crystallography (see, e.g., Vijay-Kumar et al., *Proc. Natl. Acad. Sci. USA* 82: 3582 (1985); Vijay-Kumar et al., *J. Mol. Biol.* 194: 525 (1987); and Vijay-Kumar et al., *J.*  
30 *Biol. Chem.* 262: 6396 (1987)) include a mixed  $\beta$ -sheet comprising two parallel inner strands (residues 1-7 and 64-72), as well as two antiparallel strands (residues 10-17 and 40-45). In addition, an  $\alpha$ -helix (residues 23-34) fits within the concavity formed by the mixed  $\beta$ -sheet.

35 The amino acid sequences which link the structural elements defined in the preceding paragraph are referred to herein as "loop regions". Thus, loop regions can be

-10-

defined as domains of ubiquitin which link either two strands within a  $\beta$ -sheet or a strand of a  $\beta$ -sheet and an  $\alpha$ -helix. Insertions and substitutions can be made within these loop regions without disrupting the integrity of the ubiquitin molecule or abolishing the features which make ubiquitin a useful carrier for the display of constrained epitopes. Insertions and substitutions within these loop regions tend not to alter the relationships between the prominent structural features defined in the preceding paragraph. Rather, the epitopes introduced into these loop regions tend to protrude from the compact globular ubiquitin structure thereby exposing these epitope residues such that they are easily recognizable by lymphocytes, for example.

As discussed above, internal modification sites are selected such that the ubiquitin secondary structure is maintained and the conformation of the inserted epitope is constrained. Epitopes can also be joined to ubiquitin as extensions of the C-terminus. Epitopes fused to the C-terminus of ubiquitin can be cleaved off by ubiquitin-specific proteases *in vivo* or *in vitro*. This allows the peptide to be administered to a cell as part of a larger fusion protein which is both easier to purify and handle as compared to free epitope. Following cellular uptake, the epitope attached to the ubiquitin can be cleaved from the C-terminus of ubiquitin and associated with a surface protein such as the MHC complex for expression on the cellular membrane.

In another embodiment, the subject invention relates to a ubiquitin fusion protein comprising ubiquitin fused to a single epitope-containing segment, the epitope-containing segment comprising two or more identical or non-identical epitopes. The epitope-containing segment can be fused to ubiquitin at its N-terminus, C-terminus or internally.

The invention relates to yet another fusion protein embodiment comprising ubiquitin fused to a single

-11-

epitope-containing segment comprising one or more identical or non-identical epitopes. In this embodiment, the epitope-containing segment is fused to the ubiquitin moiety at the N-terminus of ubiquitin.

5       The use of ubiquitin fusion proteins to initiate a humoral response is described in more detail in the following Exemplification section. More, specifically, these experiments demonstrate, for example, that the B-cell and T-cell epitopes expressed in the ubiquitin  
10 fusion protein stimulated targeted immune responses. Further, the experiments demonstrate that a humoral immune response to an internally inserted B-cell epitope was enhanced by the addition of a T-cell epitope to the C-terminus of the ubiquitin fusion protein. Although the  
15 bulk of the *in vivo* data reported herein were generated in experiments employing murine indicator assays for the generation of antibodies against the ubiquitin fusion proteins, the fundamental principles are applicable to humans as well as other animals. Given the disclosure of  
20 the subject application it is a matter of routine experimentation to select epitopes of interest and incorporate such epitopes of interest into a ubiquitin fusion protein for use as an immunogen.

      Thus, in a preferred embodiment, the ubiquitin  
25 fusion protein comprises an internally inserted B-cell epitope and a T-cell epitope joined to the C-terminus of ubiquitin. One of skill in the art can identify B-cell epitopes which have the ability to drive a strong humoral immune response following administration to an animal.  
30 The B-cell epitope which is selected will depend upon the intended use of the ubiquitin fusion protein. For instance, if the ubiquitin fusion protein is to be used as a vaccine, the B-cell epitope can be derived from a protein which is expressed by a virus, bacteria or other  
35 infectious organism associated with causing a disease. The protein which is selected should be one which contains epitopes which elicit strong antibody responses. These responses are associated with protection of the

-12-

animal species from the symptomology caused by the infectious organism. Preferably, the B-cell epitope which is selected is derived from a portion of the protein from the infectious organism known to be both  
5 highly immunogenic and to which protective antibodies can be produced. In general, this will include proteins found on the surface of the infectious organism which are involved in binding and to which antibodies have a high degree of access.

10 One example of a B-cell epitope which fulfills the requirements set forth above is the V3 loop of the HIV gp120 glycoprotein. As described in the following section, an epitope derived from the V3 loop of the HIV gp120 glycoprotein, when internally inserted within a  
15 ubiquitin fusion protein, is able to drive a strong humoral response. In fact, the antibody response was stronger than that found when the epitope was administered independently as a peptide antigen. The selection of this epitope was based on extensive data  
20 showing it is a target of neutralizing antibodies.

The selection of the B-cell epitope is not limited to proteins associated with infectious organisms. For instance, as shown in Example 2 below, when the ubiquitin fusion protein contains an internally inserted epitope  
25 from a prostate-specific antigen, a strong antibody recognition was detected. Examples of other epitopes useful in connection with the present invention include those from proteins which are commonly used as immunological "carriers" as part of experimental studies.  
30 These include hen egg lysozyme, keyhole limpet hemocyanin and ovalbumin. One of skill in the art will recognize that any protein containing a B-cell epitope which is capable of driving a humoral immune response can be included in a fusion protein of the present invention.  
35 Many such epitopes are known and others can be determined through routine experimentation.

In a preferred embodiment, a T-cell epitope is joined to the C-terminus of the ubiquitin fusion protein.

-13-

This epitope is selected based on its ability to enhance the humoral immune response directed to the internally inserted B-cell epitope when both are placed in their proper orientation with respect to ubiquitin. The preferred T-cell epitope is selected from a group of T-cell epitopes which are able to elicit "promiscuous" T-cell help. This type of T-cell epitope is commonly referred to as a universal epitope. Universal T-cell epitopes function by stimulating helper T-cells specific to the B-cells responsive to the ubiquitin fusion protein containing the internally inserted B-cell epitope. They do this regardless of the subject's MHC haplotype or whether the specific "target" protein is different than the protein the universal T-cell epitope is derived from. Examples of universal T-cell epitopes include epitopes from tetanus toxin, measles virus and Mycobacterium tuberculosis. This list of universal T-cell epitopes is not intended to be comprehensive, others which are known or can be determined through application of routine experimentation are also included.

To stimulate cytotoxic T-cells as part of a cellular immune response, T-cell epitopes are preferably inserted internally within the ubiquitin moiety. In addition, it is preferable to fuse at least one T-cell epitope to the C-terminus of the ubiquitin fusion protein. In this case, the T-cell epitopes are selected on the basis of their ability to ensure stimulation of cytotoxic T-cells specific for the particular epitope. However, a universal T-cell epitope can be attached to the C-terminus of the ubiquitin fusion protein to enhance the stimulation of the specific T-cell response.

Cytotoxic T-cells play an important role in the surveillance and control of viral infections, bacterial infections, parasitic infections and cancer, for example. Vaccination with synthetic epitopes, or with epitope pulsed cells, has been shown to induce specific cytotoxic T-cell responses directed against immunogenic viral or tumor-derived epitopes. Alternative protocols of T-cell

-14-

activation allow the triggering of more selective cytotoxic T-cell responses with greater therapeutic effectiveness.

Generally, the fusion of peptides to the C-terminus of ubiquitin generates a construct which is cleavable, in vivo, by ubiquitin-specific proteases. It is well-established that such ubiquitin-specific proteases cleave ubiquitin fusions after a C-terminal residue (residue 76), thereby releasing the C-terminal peptide. The present invention also encompasses ubiquitin fusion proteins which have been modified such that the fusion is not efficiently cleaved by ubiquitin-specific proteases. As is well known to those of skill in the art, ubiquitin can be made resistant to ubiquitin-specific proteases by altering residues at the C-terminus of ubiquitin. For example, by altering the identity of the amino acid at position 76 of ubiquitin (e.g., from glycine to valine or cysteine), the rate of cleavage of a C-terminal ubiquitin fusion can be substantially reduced to the point where cleavage can not be detected using the assays typically employed for monitoring such cleavage.

As mentioned previously, the present invention also encompasses fusions to the N-terminus of ubiquitin. It is noted that fusion proteins in which an epitope or epitopes are attached to the N-terminus ubiquitin must be designed such that the N-terminal residue of the encoded fusion protein is methionine. If the N-terminal residue is a residue other than methionine, initiation of translation does not occur efficiently. Unfortunately, however, previous studies have demonstrated that fusions of this type can reduce antibody binding or elicit the production of antibodies of low affinity for the epitope fused to the N-terminus of ubiquitin.

To overcome this problem, a tandem ubiquitin fusion is created by attaching a second ubiquitin protein to the N-terminus of the epitope or epitopes attached to the N-terminus of the first ubiquitin moiety. Thus, in this embodiment of the present invention, two ubiquitin

-15-

molecules flank an epitope or epitopes. The C-terminus of the N-terminal ubiquitin protein is of the wild-type sequence such that it is cleavable by ubiquitin specific proteases. DNA encoding this tandem ubiquitin fusion is used to transform either prokaryotic or eukaryotic cells. Previous work has shown that the tandem ubiquitin fusion is produced at an equivalent or increased level as compared to the single ubiquitin fusion proteins.

Following purification, the tandem ubiquitin fusion can be cleaved, *in vitro*, by a ubiquitin specific protease thereby releasing the N-terminal ubiquitin protein from the core fusion protein which is comprised of an epitope attached to the N-terminus of the C-terminal ubiquitin protein.

The C-terminal ubiquitin protein in the tandem ubiquitin fusion protein can be modified by the inclusion of other epitopes in a manner consistent with the description of the invention above. Thus, fusion can be made within the C-terminal ubiquitin molecule or to the C-terminus of the C-terminal ubiquitin molecule.

An alternative tandem ubiquitin construct suitable for use in connection with all embodiments of the present invention is encompassed within the scope of the present invention. More specifically, in the alternative tandem ubiquitin construct, the two ubiquitin moieties are contiguous (i.e., the N-terminus of a first ubiquitin moiety is joined to the C-terminus of a second ubiquitin moiety). In this embodiment, the N-terminal residue of the first ubiquitin moiety is a residue other than methionine. This first ubiquitin moiety is then fused to a wild-type ubiquitin moiety which is cleavable by a ubiquitin-specific protease.

Alternatively, the second ubiquitin moiety in this tandem construct need not be a complete ubiquitin moiety. Rather, a C-terminal subdomain of ubiquitin competent to direct cleavage by a ubiquitin-specific protease, is sufficient. In addition, in connection with this and any other embodiment of the present invention, ubiquitin (or



-16-

portions thereof) may be modified to inhibit cleavage by a ubiquitin-specific protease.

A variant of one of the two major embodiments of the present invention is a ubiquitin fusion comprising a first and a second epitope-containing segment inserted internally, and a third epitope-containing segment fused to the C-terminus of ubiquitin. The subject invention encompasses a wide range of such variant embodiments. There is no theoretical limit on the number of epitopes which can be inserted within or fused to the N and C-terminus of a ubiquitin fusion protein.

In preferred embodiments, internally fused epitopes are fused as single epitopes, non-contiguously. This design ensures that antibodies produced following vaccination are specific for a single epitope and do not cross-react with other epitopes which have also been internally fused to ubiquitin. Thus, each epitope elicits a specific antibody response by producing antibodies which do not cross-react with other epitopes contained within the same ubiquitin fusion protein. The use of an epitope-containing segment in which two or more distinct epitopes are displayed is preferred when attempting to create bifunctional antibodies for experimental, diagnostic or therapeutic uses.

In another embodiment of the present invention, an epitope-containing ubiquitin fusion protein is modified by conjugation to a carrier protein such as ovalbumin (OVA) or keyhole limpet hemocyanin (KLH). Example 5, presented below, exemplifies such an embodiment.

Ubiquitin fusion proteins of the type described above can be modified post-translationally by the addition of fatty acids to enhance immunogenicity. For example, palmitic acid ( $C_{16}$ ) can be added using appropriate chemistry for this purpose.

The discussion above has focused on a wide variety of epitope-containing ubiquitin fusion proteins. The invention also relates to DNA expression constructs which encode such epitope-containing ubiquitin fusion proteins.

-17-

These constructs can be based on prokaryotic expression vectors or eukaryotic expression vectors. Many examples of such expression vectors are known in the art. Prokaryotic expression vectors are useful, for example, for the preparation of large quantities (e.g., up to milligram quantities) of the ubiquitin fusion protein. Eukaryotic expression vectors are useful, for example, when the addition of carbohydrate side chains (i.e., glycosylation) is important. The carbohydrate side chains can affect the properties of a protein in a variety of ways including, for example, the ability of the protein to function *in vivo* or *in vitro*; the ability of the protein to form a complex and associate with other proteins or nucleic acids; and the ability of the protein to bind to an antibody or other molecules specific for the protein of interest.

In another aspect, the present invention relates to methods of vaccination. The vaccine can be used to drive a cellular and/or humoral immune response depending on the type of epitopes fused to the ubiquitin fusion protein. The therapeutic amount of the ubiquitin fusion protein given to an animal species will be determined as that amount deemed effective in eliciting the desired immune response. The ubiquitin fusion protein is administered in a pharmaceutically acceptable or compatible carrier or adjuvant.

Thus, the present invention also encompasses pharmaceutical compositions for the administration of ubiquitin fusion proteins. Examples of specific diseases which can be treated in this manner include, for example, gastrointestinal diseases, pulmonary infections, respiratory infections and infection with HIV. The pharmaceutical compositions are prepared by methods known to one of skill in the art. In general, the ubiquitin fusion protein is admixed with a carrier and other necessary diluents which are known in the art to aid in producing a product which is stable and administrable. Administration of the pharmaceutical composition can be

-18-

accomplished by several means known to those of skill in the art. These include oral, intradermal, subcutaneous, intranasal, intravenous or intramuscular.

Conventional vaccination methods involve the administration of an epitope-containing protein. Recently, and alternative to conventional vaccination methods, referred to as DNA vaccination, has been developed. In this method, DNA encoding the epitope-containing protein is introduced into the cells of an organism. Within these cells, the epitope-containing protein is directly expressed. Direct expression of the ubiquitin fusion proteins of the present invention by endogenous cells of a vaccinated animal allows for the continual stimulation of humoral and cellular immune responses over an extended period of time. This is in contrast to standard immunization protocols whereby the vaccine is injected at a single site one or more times. Following injection, the vaccine is disseminated to lymphoid organs where a single immune response occurs.

Direct expression can be accomplished by introducing DNA constructs which encode the desired ubiquitin fusion protein into the cells of an animal. The constructs typically contain promoter elements and other transcriptional control elements which direct the expression of the ubiquitin fusion protein. Introduction of the DNA construct can be by any conventional means including direct injection. The preferred administration site is muscle tissue or tissues rich in antigen presenting cells.

The introduction of a ubiquitin fusion protein as described above can also induce a tolerizing effect on the humoral or cellular immune response in an animal. Tolerization occurs following delivery of the ubiquitin fusion proteins to T-cells. The induction of a tolerization response is useful, for example, in connection with the treatment of allergic or autoimmune disorders. Examples of epitopes which can be used in a therapeutic regimen designed to induce tolerization

-19-

include the Fel d 1 peptides, which are the major allergens found in cat pelts. These peptides can be internally inserted, for example, and fused to a cleavable C-terminus of ubiquitin. Typically patients to  
5 be treated are dosed subcutaneously with the ubiquitin fusion proteins once per week for several weeks. However, dosing can also be done orally or intranasally over a similar length of time. The result is a reduction of the allergic and/or autoimmune responses. These  
10 ubiquitin fusion proteins can also be given orally.

The use of ubiquitin as a scaffold for the presentation and stimulation of immune responses also allows the stimulation and generation of anti-self responses. Anti-self responses are generated by  
15 immunizing an animal with a ubiquitin fusion protein which has incorporated into it an epitope derived from an endogenous (self) protein. Such epitopes are herein referred to as self-epitopes. Endogenous proteins in a healthy animal are not naturally antigenic in that  
20 animal; they do not naturally elicit an immune response. However, by presenting one or more self-epitopes to an immune system, in the context of a ubiquitin fusion protein, as described above, an immune response can be elicited which is directed towards endogenous (self)  
25 proteins, to produce an anti-self response. Endogenous proteins to which an immune response is generated is herein defined as a self-antigen or self-immunogen. Such a response to a self-antigen can result in the reduction of the endogenous protein to levels significantly below  
30 base line.

An example of a potentially valuable anti-self response is the generation of anti-GnRH (gonadotrophin releasing hormone) antibodies. As described in Examples  
3 below, efforts have been made to generate immunogens  
35 which stimulate a strong anti-GnRH response which results in the suppression of luteinizing hormone (LH) and follicle stimulating hormone (FSH) and indirectly suppresses the production of the steroidogenesis and

-20-

gamete maturation in both males and females. The value of this type of anti-self response in humans lies in the treatment of prostate cancer and breast cancer.

5 In livestock and pets, the ability to stimulate an anti-self response provides a simple alternative to physical castration, as demonstrated Examples 6, 9 and 10. Previous work employing complex immunogens has demonstrated varying degrees of success in immunological castration. However, the production of complex  
10 immunogens is cumbersome, typically involving a combination of synthetic chemistry, expensive HPLC purifications, and chemical coupling methods. The use of ubiquitin fusion proteins containing GnRH epitopes facilitates the production of inexpensive and potent  
15 immunogens for use in connection with immunocastration. In particular, ubiquitin fusions which include the peptide QHWSYGLRPGQHWSYGLRPGQHWSYGLRPGQHWSYGL-RPGC are of interest.

Immunocastration of pigs is especially valuable  
20 since it does not result in the detrimental side-effects associated with physical castration. More specifically, physical castration of pigs typically results in animals which do not grow as well as normal animals. In addition, physically castrated pigs tend to have a higher  
25 fat percentage than non-castrated pigs. Since, immunocastrated animals are not castrated as early as those which undergo normal physical castration, a farmer can take advantage of the growth rates found with non-castrated animals. Finally, by immunocastrating, the  
30 farmer avoids the production of unpalatable meat found with uncastrated male pigs.

Other examples of self proteins which could be used with ubiquitin to generate vaccines able to modulate the hormones, cytokines and physiology of humans and animals  
35 are: growth hormone and its peptides to modulate growth both negatively and positively; TNF and its epitopes to modulate septic shock, arthritis, inflammatory bowel disease, crohn's disease, and ulcerative colitis;

-21-

immunoglobulin epsilon heavy chain for the control of allergic reactions; chorionic gonadotrophin for fertility control; inhibit for fertility control; and Sperm proteins such as sp17 (for example amino acids 4-19 and 118-127) and the 71kd sperm protein for control of fertility both in men and in women.

A further use of ubiquitin as a scaffold is as part of a vaccine to enhance the growth rate and thereby the final weight of livestock prior to shipment to market. This type of vaccine offers a cost effective means to increase the value of livestock such as pigs, cattle and other commonly raised animals. Presently, to increase the weight of livestock several methods are being utilized. Amongst these methods, the addition of antibiotics to the feed has become very common. However, while addition of antibiotics to feed is cost effective, it has limitations. For instance, it has been blamed for an increase in the creation of antibiotic resistant strains of bacteria.

An alternative means to increase the growth rate of livestock which does not result in detrimental side-effects is through vaccination of the animals with an epitope of growth hormone which is part of a ubiquitin fusion protein. The result of this vaccination is an increase in the activity of the animals endogenous growth hormone. The vaccine is created by inserting an epitope from the growth hormone protein (e.g., amino acids 54-95) into the ubiquitin protein thus creating a ubiquitin-growth hormone fusion protein. The effective use of this type of vaccine is described in Example 7 below. More specifically, following the injection of a vaccine comprised of adjuvant and a ubiquitin fusion protein containing the growth hormone protein epitope, the growth rate of pigs was improved when compared to control pigs which received either adjuvant only or adjuvant and ubiquitin only.

In addition to the uses described above, the ubiquitin fusion proteins of the present invention can be

-22-

used for the identification of antibodies from experimental or clinical samples. Antibodies to be assayed can be found, for example, in blood, fecal material, the linings of mucosal associated lymphoid  
5 tissues, cellular biopsies and other sources known by one of skill in the art to contain at least a minute quantity of antibody. Assays for which the ubiquitin fusion proteins are well suited include ELISAs, radioimmunoassay as well as other commonly used competition assays. These  
10 types of assays are useful in identifying antibodies from an experimental or clinical sample which have specificity to at least one epitope of a known protein. In general, the assays involve mixing a predetermined aliquot of the ubiquitin fusion protein with a series of dilutions of  
15 the experimental or clinical antibody sample. This is followed by detection of the antibodies which bind to the ubiquitin fusion protein.

Detection can be accomplished by various means, but for the present invention, a labeled detection antibody  
20 is preferable. For example, if the experimental or clinical antibody sample is from a human, the detection antibody can be a polyclonal antibody with specificity for the human heavy chain portion of the sample antibody. The detection antibody is attached to either an enzymatic  
25 label, a radioactive label or a fluorochromatic label. Examples of commonly used enzymatic labels are horse radish peroxidase and alkaline phosphatase. A standard radioactive label includes iodine 131. Fluorochromatic labels include fluorescein and Texas red. The method of  
30 visualization of the complex containing the ubiquitin fusion protein, the sample antibody, and the labeled antibody depends on the label attached to the antibody and would be known to those of skill in the art.

-23-

EXAMPLESNo. 1

Fusion proteins consisting of short peptide sequences inserted within a ubiquitin scaffold were developed and tested as immunogens for eliciting a targeted immune response. Preparation and testing of the fusion proteins required several steps including: (I) the design and construction of plasmids encoding peptide sequences fused to the ubiquitin polypeptide at two permissive sites which could be useful for epitope display; (II) the high-level expression in *E. coli*, purification and characterization of the expected ubiquitin fusions; and (III) evaluation of the immune response in mice with regard to immunogenicity, antibody specificity, cross-reactivity and helper T-cell response. Fusion proteins were developed to display the sequence of the HIV-1 gp120 V3 loop, the principal recognition determinant of virus neutralizing antibodies.

Materials and MethodsMice

BALB/c, C57BL/6 and C3H/HeN female mice at 6-8 weeks of age were obtained from Charles River (Frederick, MD) or Jackson Labs. Animals were housed and cared for in an IACUC supervised facility in accordance with an NIH approved Animal Welfare Assurance.

Peptides, proteins and antibodies

Bovine ubiquitin (Sigma, St. Louis MO) was dissolved in PBS and filtered through a 0.2 micron filter. Goat anti-mouse peroxidase conjugate was used as obtained from Promega. Mouse monoclonal antibodies against V3 peptides of gp120MN (HG-1) and gp120IIIB (# 13-105-100) were purchased from Biodesign International (Kennebunk, ME) and from Advanced Biotechnologies Inc. (Guilford, MD) respectively. Recombinant proteins gp120IIIB and gp120MN and a 36 residue "universal" V3 peptide



-24-

CTRPNNNTRKSIHIGPGRAFYTTGEIIGDIRQAHG (SEQ ID NO:1) were obtained from Intracel Corporation (Cambridge, MA). Synthetic peptides KRIHIGPGRAFYTTK (L-V3) (SEQ ID NO:2) and CKSIHIGPGRAFYTTGC (C-V3) (SEQ ID NO:3) were obtained  
5 through the AIDS Research and Reference Reagent Program, Division of AIDS, NIAID, NIH: from Peptide & Protein Research Consultants (Exeter, Devon, UK).

#### Oligonucleotide design

Oligonucleotides were obtained by custom synthesis  
10 through Bioserve Biotechnologies. Sequences shown below were designed to encode peptide sequences and to provide appropriate complementary overhangs for ligation to restriction sites in plasmids. Oligonucleotides were treated with T4 polynucleotide kinase and complementary  
15 pairs were annealed by heating to 65EC for 5 minutes, then cooling to room temperature over 30 minutes.

A 5'-TTAAGACTGCGTGGCGGCGACCA  
GGTTCACTTCCAGCCGCTGCCGCCGGC-3' (SEQ ID NO:4)  
B 5'-TGTTGTTAAACTGTCTGACGCTC  
20 TGTAAGCTTCTGCA-3' (SEQ ID NO:5)  
C 5'-GAAGCTTACAGAGCGTCAGACAGTTTA  
ACAACAGCCGGCGGCA-3' (SEQ ID NO:6)  
D 5'-GCGGCTGGAAGTGAACCTGGTCGCC  
GCCACGCAGTC-3' (SEQ ID NO:7)  
25 E 5'-TTAAGACTGCGTGGCGCTGACCAGGTTCACT  
TCCAGCCGCTGCCGCCGGC-3' (SEQ ID NO:8)  
F 5'-GCGGCTGGAAGTGAACCTGGTCA  
GCGCCACGCAGTC-3' (SEQ ID NO:9)  
G 5'-AAGAAATCCACATCGGTCCGGGTCGTGCTTT  
30 CTACACCACCATCCCGCCGGATCA-3' (SEQ ID NO:10)  
H 5'-ATCCGGCGGGATGGTGGTGTAGAAAGCACGA  
CCCGGACCGATGTGGATTCTTT-3' (SEQ ID NO:11)  
I 5'-TTAAGACTGCGTGGCGG  
CATCCACATCGGTCCG-3' (SEQ ID NO:12)  
35 J 5'-GGTCGTGCTTTCTACAC  
CACCTAACTGCA-3' (SEQ ID NO:13)

-25-

K 5'-GTTAGGTGGTGTAGAAAGC  
ACGACCCGGACCGAT-3' (SEQ ID NO:14)  
L 5'-GTGGATGCCGCCACGCAGTC-3' (SEQ ID NO:15)

#### Strains and vector construction

5 Ubiquitin fusions were cloned and expressed in the  
Proteinix proprietary *E. coli* strain DH5 $\alpha$  F' IQ<sup>TM</sup> (Life  
Technologies). Vector constructs for expression of  
fusion proteins are derivatives of pDSUB (provided by M.  
Rechsteiner, Univ. of Utah), which is a derivative of  
10 pDS78/RBSII. The ubiquitin codon usage was optimized for  
expression in *E. coli*. Transformants containing pDSUB or  
its derivatives were selected for ampicillin resistance.  
Ubiquitin fusion expression, under control of the lac  
promoter, is inducible by addition of IPTG. Cloning at  
15 the ubiquitin codon 35 was initially performed in  
pRSETub, derived from pRSET (Invitrogen, Inc.) by  
subcloning of the ubiquitin gene from pDSUB to pRSET  
utilizing the Nde I and Hind III restriction sites.  
Restriction sites for insertions at codon 35 of ubiquitin  
20 were created by *in vitro* mutagenesis with a synthetic  
oligonucleotide using the MORPH mutagenesis kit (5 Prime-  
3 Prime, Inc.) to obtain pPX153. Digested vector  
fragments were treated with calf intestinal alkaline  
phosphatase and purified from agarose gel slices after  
25 electrophoresis using the Geneclean kit (Bio 101).  
Vector fragments and double stranded oligos were ligated  
and products were used for cloning in *E. coli* strain  
DH5 $\alpha$ F' IQ<sup>TM</sup> (Life Technologies). All restriction digests,  
ligations and transformation of *E. coli* were done  
30 according to standard manipulations using commercial DNA  
modifying enzymes as instructed by the manufacturer (New  
England Biolabs). Correct cloning of the oligonucleotide  
insertions was confirmed by DNA sequencing using the  
Sequenase Version 2.0 kit (USB, Cleveland, OH).

-26-

Expression, purification and characterization of fusion proteins

Cell paste from bacterial fermentation was resuspended in lysis buffer (5 ml/g wet paste) with vortexing. General purpose buffer consisted of 20 mM MES pH 5.5, supplemented with 1 mM PMSF, 0.5 mM ZnCl<sub>2</sub>. Cultures expressing certain fusion proteins were lysed in 50 mM acetate pH 4.0 (UbaMT) or pH 4.5 (UbgMT). Cells were disrupted by sonication on ice 2 x 4 min with a 50% duty cycle. Homogenates were centrifuged at 15,000 x g, 45 min, 4EC. The supernatants were further diluted with 3 volumes of lysis buffer, filtered through a 0.45 µm filter, and loaded onto a 30 mL SP sepharose HP ion exchange column at a linear flow rate of 1.4 cm/min. The fusion protein was eluted by a NaCl gradient (0-0.5 M) over 16 column volumes. Fractions were assayed by SDS-PAGE on 10-20% tricine gels (Novex, San Diego CA) and protein concentration was determined by the BCA method (Pierce Co.) using a ubiquitin standard curve. Peak fractions were pooled and evaluated further by C18 reversed phase HPLC on a Vydac 218TP54 column using a gradient of 30-45% acetonitrile in water containing 0.1% TFA over 7 min at 1.00 mL/min, with UV detector set at 214 nm.

Immunoblots were prepared by electroblotting of samples from SDS-PAGE gels onto Immobilon-P membrane (Millipore Corp.) using an X-Cell II Blot Module (Novex). The membranes were incubated in PBS containing 4% dry milk overnight and then washed with PBS. Incubations with primary antibody were done in PBS, 0.1% Tween 20 for 2 hr at room temperature. After 3 washes with the dilution buffer, membranes were incubated with goat anti-mouse IgG HRP conjugate at 1:5000 dilution in the same buffer. The wash steps were repeated and the membrane was developed with ECL Western detection reagents kit (Amersham, Waltham, MA) according to the manufacturer's instructions.

-27-

In vitro cleavage of Ubiquitin fusion proteins by UBP

Reactions of UbV3gMT, UbgMT and UbaMT were monitored by C18 reverse phase HPLC on a Vydac 218TP54 column with detection at 214 nm using a 10 min gradient of 20-50% acetonitrile in water containing 0.1% TFA, and by SDS-PAGE on 10-20% tricine gels. Aliquots of fusion protein (100-200 Fg) were diluted into 200 FL of 50 mM Tris pH 8.0, 5mM DTT, 1 mM EDTA. A 1 FL aliquot of UCH-L3 (2 ug) or reaction buffer (control) was added and the samples were incubated at 37EC and monitored over 1 hr by HPLC. SDS-PAGE samples were run after 2 hrs reaction time.

For large scale digests, purified UbgV3 from SP sepharose HP ion exchange was concentrated 3-fold by Centriplus 3 membrane concentrators. The final concentration of fusion protein was 2.1 mg/ml. The fusion protein in 12 ml of buffer was buffered with 631 FL of 1 M Tris pH 8.0, 64.8 uL 1 M DTT, 24.0 uL 0.5 M EDTA. UCH-L3 (0.24 mg in 120 FL) was added and the reaction was incubated at room temperature and monitored by HPLC. The product peptide peak was purified by semi-preparative C18 HPLC (Vydac 218TP510 1.0 cm diameter column) and lyophilized to yield the V3 peptide IHIGPGRAFYTT (SEQ ID NO:16). Identity was verified by FAB-MS. The MT peptide DQVHFQPLPPAVVKLS DAL (SEQ ID NO:17) was obtained by a similar procedure from ion exchange purified UbgMT (4.82 mg/ml). The peptide product was isolated from semi-preparative C18 HPLC using a 20-40% gradient of acetonitrile in 20 mM potassium phosphate, pH 6.0 over 8 min. The peptide content in the lyophilized product was estimated at 10% by weight based on HPLC peak area.

Immunization protocols and mouse lymphocyte proliferation assay

Mice were inoculated in groups of 3 to 5 per antigen by an initial subcutaneous (s.c.) injection of 100 Fg of proteins in PBS emulsified in an equal volume of complete Freund's adjuvant (CFA) or incomplete Freund's adjuvant

-28-

(IFA). Booster injections of proteins (100 Fg) were delivered intraperitoneal in IFA 3 weeks and 7 weeks later. Blood samples were collected at 4 weeks, 6 weeks, 8 weeks and 10 weeks from the initial injection. Serum  
5 was separated and diluted in PBS.

For preparation of sensitized T-cells, mice were immunized in groups of 3 by injection s.c. in footpads with 50 Fg of proteins in PBS emulsified in IFA. Eight to ten days later mice were sacrificed and popliteal  
10 lymph nodes (LN) were removed aseptically. LN cell suspensions in RPMI 1640 were prepared as described and dispensed into 96-well plates at  $5 \times 10^5$  cells per well. Antigens or peptides were added in triplicate wells and plates were kept in a CO<sub>2</sub> incubator at 37EC for 4 days.  
15 Wells were then pulsed with 3H-deoxythymidine (1 FCi/well) and cells were harvested on filter pads 24 hours later using an automated collecting device. Filter sheets were allowed to dry and then counts were read on a Wallac microbeta plate reader (Wallac, Inc., Gaithersburg  
20 MD). Stimulation was expressed as the average signal of duplicate or triplicate wells corrected for mean background counts (c.p.m. with protein or peptide - c.p.m. with buffer added).

#### Immunoassays

25 Fusion proteins (50 Fg/ml) or synthetic peptides (10 Fg/ml) in PBS were dispensed into immunosorbent 96-well plates (0.1 ml/well, Corning high binding flat bottom plates) and incubated for 1 hour at 37EC. Excess antigen was shaken out and nonspecific sites were blocked by  
30 addition of PBS containing 10 mg/ml of BSA (0.1 ml/well, incubated 30 min at 37EC). Plates were washed three times (Tris buffer 10mM, 0.1% Tween 20, pH 8) and serially diluted serum samples (1/103-1/104 in PBS supplemented with 1% BSA) were added (0.1 ml/well).  
35 After 1 hour at 37EC plates were washed as before and developed with affinity purified goat anti-mouse IgG-horse radish peroxidase conjugate (0.5 Fg/ml in PBS

-29-

supplemented with 1% BSA, 0.1 ml/well). After washing, bound enzyme was detected with o-phenylenediamine (1 mg/ml in phosphate-citrate buffer, 0.05M, 0.02% H<sub>2</sub>O<sub>2</sub>, pH 5). Plates were read at 450 nm on a 96-well plate reader (Titertek). Titters are expressed as the dilution of serum giving an absorbance reading of 0.3 or 15% of the maximum reading.

Solution phase binding assays were performed by incubating peptides or proteins at concentrations ranging from 0.5-50 Fg/ml with antiserum in 0.1 M potassium phosphate, 2 mM EDTA, 10 mg/ml BSA, pH 7.8 at a fixed concentration of 2-fold greater than the previously determined titer dilution. Samples were incubated at 37EC for 2 hours, then applied to antigen-coated ELISA plates. The standard ELISA procedure was followed to determine the concentration of unbound antibody relative to samples containing no added ligand.

## Results

### Plasmid construction and sequences

Sequences of the oligonucleotides encoding for peptide inserts and their letter designations are given above. Linearized DNA from pDSUb restriction digested with Afl II and Pst I was ligated to double-stranded oligos A/D and B/C to obtain pDSUbGMT. Similar ligation to oligos E/F and B/C provided pDSUbaMT. Double stranded oligos G/H were ligated to the 1.2 kb and 1.6 kb fragments obtained from digest of pPX153 with restriction enzymes Xcm I and Bpm I to provide the V3 insertion at codon 35 of ubiquitin.

The new vector pRSETUbV3 was digested with Bgl II and Afl II, and the smaller fragment encoding UbV3 was gel purified. Ligation of this fragment to pDSUb, pDSUbGMT or pDSUbaMT, each digested with Bgl II and Afl II, generated expression vectors pDSUbV3, pDSUbV3gMT, and pDSUbV3aMT respectively. These were used to express the internal UbV3 fusion and double epitope fusions with a 19-residue C-terminal extension DQVHFQPLPPAVVKLS DAL (MT

-30-

sequence) (SEQ ID NO:17) and either native (RGG) or mutant (RGA) protease recognition site at the ubiquitin C-terminus. A vector encoding ubiquitin fusion with a C-terminal 12-residue V3 sequence was assembled as follows:  
5 pDSUB was digested with Afl II and Pst I and the product ligated to paired oligos I/L and J/K to obtain pDSUBV3c.

#### Expression yield and purification

Fermentations in 10 L batches provided 150-175 g of wet cell paste. Fusion protein yields after a single ion  
10 exchange chromatography step ranged from 185 mg to 336 mg per 15 g of cell paste, equivalent to 1 L of culture. Product was isolated from 1-2 L shaker flask cultures (UbgV3) with similar results and yields. Fusion proteins UbgMT and UbaMT required chromatography with 50 mM acetic  
15 acid pH 4.0 and pH 4.5, respectively for retention on the ion exchange matrix. Ubiquitin fusions purified by ion exchange were greater than 98% pure as judged by SDS-PAGE.

#### In vitro cleavage of C-terminal Ubiquitin fusions with 20 UCH-L3

Processing of ubiquitin fusion polypeptides by the ubiquitin C-terminal hydrolase UCH-L3 is presumed to depend on recognition of the native structure of the ubiquitin domain. Analytical digests of UbV3gMT and  
25 UbgMT by UCH-L3 proceeded with similar efficiency as shown by the HPLC and SDS-PAGE results. Cleavage of the UbV3gMT having an internal fusion in the ubiquitin sequence suggests that an insert in the 34-40 loop does not interfere with folding of ubiquitin or recognition by  
30 the enzyme. The reaction can be followed by the formation of peptide product detected by HPLC analysis. SDS-PAGE analysis is useful for determining completion by depletion of substrate and formation of a band corresponding in size with ubiquitin.

35 The enzymatic digest of ubiquitin fusions is a practical bioprocess for production of peptides. Two

-31-

short peptides, IHIGPGRAFYTT (SEQ ID NO:16) and DQVHFQPLPPAVVKLSDAL (SEQ ID NO:17), useful in this study, were conveniently prepared by processing of recombinant C-terminal ubiquitin fusions.

5 Binding and specificity of anti-V3 peptide antibodies to UbV3

Antibodies that neutralize HIV-1 infectivity are directed against the V3 loop or principal neutralizing determinant (PND) of gp120. The PND is implicated in  
10 several viral mechanisms known to evade the humoral immune response. Subunit vaccines based on the native structure in gp120 indicate only weak immunogenicity toward this region. Variability of the V3 loop in divergent viral isolates and depletion of B-cells  
15 producing antibodies to the PND in infected individuals could also allow for HIV-1 escape from immune surveillance. The gp120 V3 loop has been studied in the context of hybrid protein scaffolds or peptide fusions as a means of producing immunogens that could induce  
20 neutralizing antibodies against HIV-1. These materials could be important as components of an effective vaccine for combating the virus.

Monoclonal antibodies raised against synthetic V3 peptides which are known to react with gp120 were tested  
25 for binding to the recombinant UbV3 by ELISA. The antibody HG-1 specific for gp120 from the HIV-1 strain MN bound to UbV3 and to a 36-residue synthetic V3 loop "universal" peptide with similar efficiency. The binding to UbV3 was inhibited by preincubating the antibody with  
30 the 36-residue V3 peptide. Absorbance was reduced by 50% in the presence of 0.5 Fg/ml peptide. Antibody specific for gp120 of the IIIB strain did not bind UbV3.

Ubiquitin fusion proteins analyzed by SDS-PAGE were transferred to nitrocellulose membranes for Western blot  
35 assays. Strong staining was seen when membranes were developed with mAb HG-1 which is specific for the V3 sequence of gp120 from HIV-1 strain MN. No staining



-32-

occurred with the mAb derived against the V3 peptide of gp120 of strain IIB.

Immunogenicity of Ubiquitin and Ubiquitin fusion proteins

Immune responses in mice were evaluated from  
5 antiserum titers and from comparison at fixed dilutions  
of antisera taken at different times after immunizations.  
Reactivity against ubiquitin, UbV3 and UbGMT proteins,  
displaying either native ubiquitin epitopes alone, the  
"V3" epitope at the internal site or the MT sequence at  
10 the C-terminal site were assessed by ELISA with the  
proteins adsorbed to the solid support.

In the BALB/c (H-2d) strain a strong immune response  
was observed after an initial inoculation and one boost  
of either UbV3, UbV3aMT, or UbV3gMT fusion proteins. In  
15 contrast ubiquitin, given by an analogous protocol, was a  
poor immunogen (Table 1). Mice receiving two or more  
injections of ubiquitin over 4 weeks generally showed  
decreasing anti-ubiquitin reactive antibody. Mice  
immunized with fusion proteins UbV3, UbV3aMT and UbV3gMT  
20 produced antiserum specific for UbV3. The anti-UbV3  
response continued to increase after an additional boost.  
Average titers of the final sera collected were in excess  
of 1:105. The antibody in these sera was shown to be  
primarily IgG. The V3 insert was the dominant B-cell  
25 target in all three immunogens. The sera bound only  
weakly or not at all to native ubiquitin or the UbMT  
fusion. Animals receiving UbGMT or UbaMT developed  
measurable antibody against UbGMT and ubiquitin. This  
response was directed partly to the C-terminal peptide as  
30 suggested by the higher ELISA signals obtained against  
the fusion protein compared with those against ubiquitin  
(Table 1).

Table 1

Summary of Immune Response Specificity to Antigens Displaying Heterologous and Native Ubiquitin Epitopes

Strain:	BALB/c	Adjuvant:	C F A , o r PN222/IFA		
Routes:	SQ, IP				
9 Immunogena	//	Antigenb6	Ub-V3	Ub-MT	Ub
Ub-V3-rgg-MT			+++	+/-	--
Ub-V3-rga-MTc			+++	+/-	--
Ub-V3-rgg			++	-	--
Ub-rgg-MT			+/-	+++	+
Ub-rga-MTc			--	++	+

- (a) Fusion proteins were purified from *E. coli* lysates and purified by ion exchange chromatography. Solutions in Tris buffer, pH 7.4 were emulsified with Freund's complete adjuvant and injected as described.
- (b) Antigens used to coat microtiter plates for ELISA were prepared from recombinant *E. coli* extracts and purified by ion exchange. Three antigens used displayed a single (V3 or MT) or no (Ub) heterologous epitope. Immunoreactivity is indicated by the relative scale from no reaction (--) to strongest reaction (+++). Borderline reactivity (signal at the highest concentration of antisera used) is scored as +/-.
- (c) Proteins with C-terminal fusions were produced with the native (rgg) and a mutated (rga) ubiquitin C-terminal sequence to test for stability to or assisted processing of the T-cell epitope by endogenous ubiquitin C-terminal hydrolases that may be present in antigen processing cells.

Immune responses to cleavable and noncleavable C-terminal fusions

- Double epitope fusions had either the native ubiquitin C-terminus (UbV3gMT), retaining the processing site (RGG) for cleavage by cellular ubiquitin-specific proteases (UBPs), or a single residue mutation expressing the sequence RGA at the ubiquitin C-terminus (UbV3aMT), that is resistant to processing. Immunizations with the two types of double-epitope fusions were compared to determine if processing by UBPs in antigen presenting cells could influence a T-helper response. Since the antibody response to the V3 site was independent of the MT epitope in the BALB/c mouse, the effect of the processing mutation could not be observed in this strain. The immunogenicity in C57BL/6 (H-2b) and C3H (H-2k) mouse strains was determined after similar treatment. In both strains a specific anti-UbV3 or UbV3gMT. Responses

-34-

against UbV3aMT were comparable in the two mouse strains when evaluated after two injections given two weeks apart. Immunoassays against ubiquitin and UbGMT, determined at 1/4000 serum dilution, indicated significantly lower antigenicity of these proteins. Signals were 16 and 35% of the values against UbV3 in the H-2b and H-2k mice, respectively. A second boost of the H-2b mice with double epitope fusion UbV3aMT produced improvements in the anti-UbV3 response similar to those seen in the BALB/c mice. The anti-UbV3 antiserum persisted at 3 weeks from the boost, although the signal at 1/4000 dilution was diminished by about 50% from sera collected in the previous bleed. Moreover, the anti-ubiquitin response was negligible in the mice that received the additional boosts. Immunizations with UbaMT produced antiserum of significant titer against all three antigens. A weaker, but similarly non-specific reaction was observed in mice inoculated with UbGMT. The anti-UbMT antisera reacted equivalently with native bovine ubiquitin and with recombinant ubiquitin but not with BSA. The anti-ubiquitin antibody persisted with additional immunizations.

#### Epitope specificity of antisera

Differences in antigenicity of the three proteins could suggest the epitope specificity of antisera for the V3 insert or the MT tag or specificity for discontinuous determinants composed of insert sequences as well as ubiquitin residues. Antiserum specific for UbV3 was incubated with short peptides analogous to the V3 sequence at varying concentrations, and residual unbound antibody measured by indirect ELISA. Reduction in signal was apparent in the 1-30 FM range of peptide concentration. By contrast, no competition was seen using ubiquitin at 10-100 FM as a competitor.

Anti-UbV3 sera reacted similarly with peptide L-V3 or a disulfide-bridged cyclic peptide C-V3 as mimics of the epitope. Although the peptide C-V3 could mimic the

-35-

conformation of the V3 loop in the fusion protein this assay did not discriminate widely between the two peptides in solution.

5        Similar conformations of the V3 insert in the UbV3 and the V3 loop structure presented in gp120 could be suggested by better cross-reactivity of the antiserum with gp120. Adsorption of recombinant gp120 to ELISA plates appears to mask the V3 epitope such that detection of antibodies is inefficient. Binding to other epitopes  
10    on gp120 was detectable by direct or sandwich capture ELISA, but this technique was less successful with anti-V3 loop antibodies. Cross-reactivity of the anti-UbV3 antiserum for gp120 was demonstrated by Western blot analysis. Solution-phase competition binding as  
15    described for the V3 peptides using accessible concentrations of gp120 (# 0.8 FM) did not produce measurable changes in the indirect ELISA.

#### T-cell proliferative responses to peptides and Ubiquitin fusions

20        LN cells from BALB/c mice immunized with fusion proteins UbV3 or UbV3MT showed a proliferative response when cultured in the presence of UbV3 fusion. No obvious stimulation was provided by V3 or MT peptides at 100 Fg/ml, suggesting that the major T-helper epitope is not  
25    found in these sequences. No proliferation was observed in the presence of native bovine ubiquitin. In order to control for possible mitogenic contaminants contributed from the *E. coli* extracts, mice were immunized with recombinant ubiquitin or with buffer. LN cells from  
30    these mice were incubated in the presence of ubiquitin or UbV3. No proliferation was observed in any case. Potential T-helper epitopes in UbV3 could include sequences spanning the inserted residues and flanking ubiquitin sequences. Peptides representing these regions  
35    should be prepared and tested in the assay to address this point.

-36-

LN cells from C3H mice immunized with UbV3aMT were marginally stimulated by UbV3. However, incubation in the presence of increasing concentration of MT peptide, but not the V3 peptide, produced a significant proliferation signal. No stimulation was observed in the same experiment when C3H mice were immunized with UbV3. These preliminary experiments did not allow quantitation of the relative efficiency of T-cell stimulation by peptide and intact fusion proteins used as immunogen. Positive stimulation values were in the same range as those observed in the presence of concanavalin A added at 2-20 Fg/ml.

## No. 2

### Results

#### 15 Production of ubiquitin fusion proteins

Ubiquitin has been used as a scaffold for displaying multiple epitopes. These ubiquitin fusion proteins have been successfully recognized by antibodies of the appropriate specificity and analyzed using Origen technology. An immediate technological application for these ubiquitin fusion proteins that display a structurally defined antigenic epitope which is known to be a target for neutralizing antibodies is in production of diagnostic antibodies for clinical or research use. The advantages conferred by the use of ubiquitin as a scaffold include: 1) its ability to stabilize the epitopes in storage, and in in vitro assays, and 2) its ability to constrain the peptide at one or both ends, thereby conferring the appropriate conformation for antibody recognition.

A commonly used sandwich immunoassay requires two distinct monoclonal antibodies against a single macromolecular analyte, in the present case the ubiquitin fusion proteins. These antibodies are directed to nonoverlapping epitopes on the ubiquitin fusion proteins, allowing the formation of a trimeric complex, or sandwich. Typically, many monoclonal antibodies must be

-37-

screened in order to identify an appropriate pair for the immunoassay. The technology described here permits the production of monoclonal or polyclonal antibodies against structurally defined epitopes in a macromolecule. Thus, a pair of reagent antibodies for a sandwich immunoassay may be produced by design rather than by random screening. Such reagents may be employed in a wide variety of important immunoassays utilizing any number of formats that are standard in the industry.

10 Construction of ubiquitin fusion proteins

In Example 2, several ubiquitin fusions were constructed. These ubiquitin fusions contain a peptide epitope loop derived from the human PSA (prostate specific antigen). As shown in Table 2 below, ubiquitin fusion proteins contained either single or double epitope insertions on the ubiquitin scaffold. Four different versions of an antigenic PSA peptide loop from human prostate specific antigen were inserted into the ubiquitin scaffold at amino acid position 35. In Table 3 below they are labeled as Fus 5, Fus 5M, Fus 7 and Fus 7M. Four C-terminal fusions were also constructed, both individually and in various combinations with the fusions inserted into the ubiquitin scaffold at amino acid position 35. The peptides joined to the C-terminus of the ubiquitin fusions are shown below in Table 3. They include ATNAT, FLAG, PSA conpep and Fus 7 conpep. The "PSA conpep" fusions contain a modification at amino acid 76 of the ubiquitin to prevent cleavage by a ubiquitin specific protease. These fusions were produced for testing by growth and isolation from bacterial cultures transformed with DNA constructs that encode the ubiquitin fusion proteins. The bacterial lysate from these transformed cultures is nearly homogeneous with respect to protein content. Thus, dilution was sufficient for the following experimentation.

Table 2

Single and Double Insertions on the Ubiquitin Scaffold			
Fus 5	92 AA	10.44 k	KE-DVCAQVHPQKVTKFMLC -IPP (SEQ ID NO: 18)
Fus 5M	90 AA	10.24 k	KE-DVCAQVHPQKVTKFMLC -MPP (SEQ ID NO: 19)
Fus 7	90 AA	10.22 k	KE- CAQVHPQKVTKFMLC -IPP (SEQ ID NO: 20)
Fus 7M	87 AA	98.93 k	KE- CAQVHPQKVTKFM -PP (SEQ ID NO: 21)
ATNAT	104 AA	11.63 k	RGG-SLRRS SCFGG RMDRI GAQSLGCNS FRY (SEQ ID NO: 22)
FLAG	98 AA	11.22 k	RGG-DYKDD DDK (SEQ ID NO: 23)
PSA consep (W/O FUS 7)	96 AA	10.99 k	RGA-LYTKV VHYRK WIKDT IVANP (SEQ ID NO: 24)
Fus 7 consep	110 AA	12.65 k	RGA-LYTKV VHYRK WIKDT IVANP (SEQ ID NO: 25)

pI 8.20  
 pI 8.63  
 pI 8.81  
 pI 9.26  
 pI 9.65  
 pI 6.12  
 pI 9.71  
 pI 9.67

-39-

Competition analysis of single epitope ubiquitin

The polyclonal antibody raised to a KLH conjugated peptide bound to the PSA peptide in the ubiquitin fusion. This PSA ubiquitin fusion was able to act like the native PSA by competing with native PSA for binding to this polyclonal antibody in an elisa assay.

in vivo cleavage of double epitope ubiquitin fusions

The structural authenticity of the ubiquitin scaffold in maintaining the secondary structure of the PSA peptide inserted internally at position 35 was probed by an in vivo assay. The assay involved the cleavage of the C-terminal PSA peptide from the double epitope ubiquitin fusion protein by a ubiquitin specific protease. Bacteria were transformed with DNA expression constructs for a double epitope ubiquitin fusion protein, UbFus7-conpep or UbFus7-ATNAT shown above in Table 2' and a ubiquitin containing plasmid. SDS-PAGE analysis of whole bacterial cell lysates showed that the UBFus7-ATNAT ubiquitin double epitope fusion protein was cleaved in vivo, liberating the C-terminal peptide from the main body of the ubiquitin fusion protein. Following the successful cleavage of the double epitope fusion UbFus7-ATNAT by in vivo ubiquitin specific proteases, the portion of the ubiquitin fusion protein which contained the internal insertion was analyzed. Based on this cleavage activity, it was deduced that a ubiquitin fusion protein with an internal insert would maintain its basic structure despite the 15 amino acid insertion of the PSA peptide at position 35. On the other hand, UbFus7-conpep fusion protein, which was modified at the C-terminus to prevent cleavage by a ubiquitin specific protease remained intact. No ubiquitin specific protease cleavage fragments were identified with UbFus7-conpep, as expected.



-40-

Direct binding of double epitope ubiquitin fusion

The proof of concept that a double epitope ubiquitin fusion could be utilized in a sandwich assay was shown by two different direct-binding immunoassays using methods known to those skilled in the art. In one of these immunoassays, the quantity of the double epitope ubiquitin fusion protein UbFus7-Flag used in the immunoassay was kept constant, while the concentration of the anti-PSA specific polyclonal serum was diluted out from  $1 \times 10^{-2}$  to  $1 \times 10^{-5}$ . The intensity of signal for the anti-PSA specific polyclonal serum for the ubiquitin fusion protein as measured by ECL (IGEN, Inc.) decreased in a linear manner as the quantity of antibody was diluted out. A similar result was found in a second direct-binding immunoassay. In this assay, the double epitope ubiquitin fusion protein was titrated out from 10,000 ng/ml UbFus7-Flag to 0.1 ng/ml UbFus7-Flag, while the quantity of anti-PSA polyclonal serum was kept constant. As seen for the first experimental assay, the intensity of signal for the anti-PSA polyclonal serum as measured by ECL intensity decreased in a linear manner as the quantity of UbFus7-Flag was reduced. Thus, the anti-PSA polyclonal serum antibody showed a high degree of binding specificity for the double epitope ubiquitin fusions. This dual recognition supports the notion that the double epitope ubiquitin fusions can serve as calibrators in a sandwich immunoassay.

No. 3Results30 Ubiquitin GnRH immunogens

In order to generate an ubiquitin fusion protein which is able to stimulate the production of self antibodies, a fusion protein was constructed which contained a C-terminal extension to ubiquitin with the following sequence of the GnRH dimer;  
35 QHWSYGLRPGQHWSYGLRPG (SEQ ID NO:26) followed by a T-cell epitope, DDPKTGQFLQQINAYARPSEV (corona virus T-cell

-41-

epitope) (SEQ ID NO:27) or DQVHFQPLPPAVVKLS DAL (MT  
epitope) (SEQ ID NO:17). This was constructed using  
standard methods known to one of skill in the art with  
sets of synthetic oligonucleotides. The ubiquitin used  
5 in these constructs was also modified so that its last  
amino acid was replaced by a valine to render the fusions  
noncleavable by ubiquitin-specific proteases. These  
ubiquitin fusions were expressed as described in Example  
1 above and purified by ion exchange chromatography and  
10 HPLC (when necessary) following standard protocols. The  
ubiquitin fusion protein were purified to greater than  
90% purity.

The purified ubiquitin fusion proteins were then  
formulated with adjuvants as described in Example 1 above  
15 and used to immunize mice. The mice were re-immunized  
about 25-30 days following the initial immunization.  
Sera prepared following bleeds from the mice were tested  
to determine the level of epitope specific antibodies  
which were induced by the specific ubiquitin fusion  
20 proteins. The results demonstrated that the  
immunizations resulted in the induction of high levels of  
anti-GnRH antibodies.

Other immunogens which were constructed include  
ubiquitin with an internal GnRH epitope as a single and  
25 as a double epitope at position 35 of ubiquitin and T-  
cell epitopes attached at the C-terminus as described  
above. To further increase the epitope density, the  
ubiquitin fusion protein with the internal GnRH dimer at  
position 35 is also fused at its C-terminus with a dimer  
30 of GnRH followed by a T-cell epitope or with MT at the C-  
terminus followed by GnRH.

In further variations of the ubiquitin fusion  
protein design which have been described above, the T-  
cell epitope was attached at the C-terminus of ubiquitin  
35 which is then fused to the dimer or monomer sequence of  
GnRH.

The GnRH monomer can consist of EHWSYGLRPG (SEQ ID  
NO:28) with a corresponding dimer of EHWSYGLRPGEHWSYGLRPG

-42-

(SEQ ID NO:29) or a mixed dimer of EHWSYGLRPGQHWSYGLRPG (SEQ ID NO:30) or QHWSYGLRPGEHWSYGLRPG (SEQ ID NO:31). Alternatively, different GnRH monomers could be used provided such monomers are able to induce antibodies to GnRH.

No. 4

N-terminal fusions of GnRH to ubiquitin for immunocastration

Novel constructs are prepared by placing an epitope at the N-terminus of a first ubiquitin protein to create a fusion protein which can elicit a desired immune response. These constructs differ from those in the prior art by allowing placement of any epitope at the N-terminus of the first ubiquitin protein in order to produce an effective vaccine conjugate.

One use for this type of novel N-terminal epitope presentation is in the generation of an anti-self antibody response. Expression vectors capable of this include those generated for immunocastration. These vectors are based on the vaccine constructs described above in Example 3. However, in the present example, the vaccine constructs include a N-terminal ubiquitin protein fused to the N-terminus of the epitope attached to the N-terminus of the C-terminal ubiquitin protein. Linkage of the N-terminal ubiquitin protein to the N-terminal epitope is through a ubiquitin specific cleavable C-terminus. For example, in the case of GnRH, the sequence coding for (QHWSYGLRPG)<sub>n</sub> (SEQ ID NO:32), where n is from 1-8, is fused to the 3' end of the second ubiquitin protein using synthetic oligonucleotides and methods known to one of skill in the art. The resultant gene sequence contains a fusion protein comprised of an epitope flanked on its C-terminus by a C-terminal ubiquitin protein and on its N-terminus by a N-terminal ubiquitin protein. The ubiquitin proteins joined to GnRH can be used to generate a number of possible combinations

-43-

of fusion proteins containing multiple GnRH sequences and T-cell epitopes.

The fusion between the N-terminal ubiquitin protein and an N-terminal epitope can occur via an RGG native ubiquitin C-terminus and a Q at the N-terminus of the  
5 GnRH sequence. In this example, the GnRH epitope sequence is comprised of from 1 to 8 copies of the following sequence QHWSYGLRPG (SEQ ID NO:32). The fusion protein comprising the GnRH epitope flanked on both its  
10 N- and C-terminal ends may be fused to at least one T-cell epitope such as DQVHFQPLPPAVVKLS DAL (SEQ ID NO:33) at its C-terminus via a non-native ubiquitin C-terminal sequence such as RGV to render it non-cleavable by the ubiquitin specific proteases. Variations on the basic  
15 construct described above are made using different C-terminal ubiquitin fusion proteins. Examples of these can be found in Example 3 above. For instance, the C-terminal ubiquitin protein can be further modified to include GnRH epitopes (from 1 to 8 epitopes) inserted at  
20 position 35. In addition, the T-cell epitope(s) fused to the C-terminus of the C-terminal ubiquitin protein can be varied.

To prepare the N-terminal epitope ubiquitin fusion proteins, these gene constructs are placed within the  
25 expression vector described in Example 1 and used to transform *E. coli* for protein expression. The expressed protein is isolated from the *E. coli* cells by sonication followed by ion exchange purification to give a preparation which can then be subjected to the action of  
30 a ubiquitin specific protease (UBP). Digestion of the fusion protein with the UBP results in the release of the N-terminal ubiquitin protein from the N-terminus of the N-terminally fused epitope. This cleavage reaction is then subjected to a further ion exchange purification to  
35 yield a fusion protein with a GnRH epitope(s) fused to the N-terminus of the COOH terminal ubiquitin protein. The purified ubiquitin fusion protein, with its N-terminal and or C-terminal epitopes, can now be

-44-

formulated to generate the vaccine for study as described in Example 6.

No. 5

Conjugation of ubiquitin GnRH fusion proteins to carrier proteins

Ubiquitin fusion proteins containing peptide epitopes can be efficiently coupled directly to another protein. In the present example, two ubiquitin-GnRH fusion proteins are created which are site specifically coupled to ovalbumin. These ubiquitin-GnRH fusion proteins are constructed using synthetic oligonucleotides, which encode the GnRH sequence; QHWSYGLRPGQHWSYGLRPGQHWSYGLRPGQHWSYGLRPGC (SEQ ID NO:34) for one construct and QHWSYGLRPGQHWSYGLRPGQHWSYGLRPGQHWSYGLRPG (SEQ ID NO:35) for the second construct.

These oligonucleotides are cloned into the UBP-cleavable C-terminal site in the coding sequence of ubiquitin as described above in Example 1. The resulting fusion constructs consist of the coding sequence for ubiquitin fused to four copies of the GnRH epitope, with both containing either a C-terminal Cys or not. To regulate expression, the coding sequence was placed under the control of a lac promoter which when induced elicits high levels of expressed fusion protein. The resulting construct is used to transform *E. coli* as described above in Example 1 and the cells were cultured followed by induction of expression of the fusion protein. The fusion protein was isolated from the *E. coli* cell pellet by first subjecting the cells to sonication, followed by purification of the fusion protein by ion exchange chromatography.

Conjugation of ubiquitin fusions with the C-terminal Cys

Ovalbumin is activated by reaction with N-succinimidyl-3-(2-pyridyldithio)-propionate (SPDP) or by succinimidyl 4-(N-maleimido-methyl) cyclohexane-1-

-45-

carboxylate (SMCC) followed by gel filtration to remove unreacted cross linking agents. Ubiquitin fusion protein is coupled to ovalbumin by reacting it with activated ovalbumin. The resultant reaction between a free SH  
5 group present on the ubiquitin fusion protein and the activated ovalbumin results in a covalent linkage through either a thiol ether linkage with the SMCC activated ovalbumin or a disulfide bond from the reaction with the SPDP activated ovalbumin. The resultant conjugate is  
10 formulated with an adjuvant such as Quil-A, complete Freund's adjuvant (CFA) or incomplete Freund's adjuvant (IFA) and then used for immunization as described in Example 6 below.

Conjugation of ubiquitin fusions without the C-terminal

15 Cys

The ubiquitin fusion protein is coupled to ovalbumin by reacting it with ovalbumin in the presence of a cross linking agent such as disuccinimidyl suberate or gluteraldehyde (Pierce). The resultant reaction the  
20 ubiquitin fusion protein and ovalbumin results in a covalent linkage through amino groups on the ubiquitin fusion protein and ovalbumin. The resultant conjugate is formulated with an adjuvant such as Quil-A, complete Freund's adjuvant (CFA) or incomplete Freund's adjuvant  
25 (IFA) and then used for immunization as described in Example 6 below.

No. 6

Immunocastration of pigs with ubiquitin GnRH immunogens

The ubiquitin fusion protein immunogens constructed  
30 as described above in Examples 3, 4 and 5 were tested in piglets. Male piglets which were between the age of 9-10 weeks were immunized with 1-10 mg of the ubiquitin GnRH immunogens in complete Freund's adjuvant (CFA) intramuscularly. Immunizations were repeated 8 weeks  
35 following the initial CFA immunization, with IFA. The piglets were slaughtered 16 weeks after the initial

-46-

immunization at which time the testicles were excised and weighed. In addition, the serum testosterone levels of the piglets was determined along with the androstenone levels in fat. All the animals immunized with the  
5 ubiquitin GnRH immunogens showed significant reduction in testicular weight, along with significantly reduced levels of testosterone in the serum. The levels of androstenone in fat were below 0.1Fg/ml. These  
10 experiments have demonstrated the potential of the ubiquitin fusion proteins to act as an immunogen for the generation of self immune responses known more specifically as immunocastration.

No. 7Growth hormone vaccine to enhance the growth rate

15 In order to improve the growth rate of pigs, a vaccine was constructed which included the insertion of a growth hormone epitope into ubiquitin. Prior studies have shown that the epitope encoded by amino acids 54-95  
20 of growth hormone can be used to make a vaccine which improves the growth rate of pigs by increasing the activity of the endogenous growth hormone. By using ubiquitin fusion proteins containing this growth hormone  
25 epitope, novel vaccines can be generated which offer the advantages of enhanced hormone activity and lower costs.

25 In the present example, the growth hormone epitope was inserted into ubiquitin as described in Examples 3, 4 and 5 above, with the growth hormone epitope inserted at the same sites described above for the GnRH epitopes. The growth hormone epitope can be inserted as a multimer,  
30 with up to four contiguous repeats to enhance its immunogenicity. Constructs encoding the growth hormone-ubiquitin fusion proteins were transformed into and expressed in *E. coli*, followed by purification of the fusion protein by methods described above.

35 The purified growth hormone-ubiquitin fusion proteins were formulated with adjuvant and used to immunize pigs weighing 15-20 kg. CFA was used for the

-47-

first immunization followed by two subsequent booster injections with IFA. These subsequent booster injections were each given at 4 week intervals following the initial injection. Pigs were monitored until they reached a weight of 110-120 Kg at which time the animals were killed. The resultant weight gain by immunized pigs when compared to control animals receiving only adjuvant or ubiquitin only and adjuvant demonstrated the improved growth rates of the immunized pigs.

10 No. 8

Preparation of Additional Ubiquitin GnRH Immunogens

Four ubiquitin-GnRH epitope fusion proteins were generated using the pDSUb expression vector, as described in Example 1 using methods known to those skilled in the art. The fusion protein PX546 has an internal tandem repeat consisting of two copies of the GnRH epitope inserted at position 35 within the ubiquitin sequence, followed by the remaining C-terminal ubiquitin sequence. This placement of the GnRH epitope-containing segment within a loop region of the ubiquitin molecule should constrain the epitope structure based on the folding of the ubiquitin protein. The fusion protein PX548 has the native ubiquitin sequence fused at the C-terminal end to four consecutive copies of the GnRH epitope, the GnRH epitope-containing segment having an additional C-terminal cysteine. The fusion protein PX549 is identical to PX548 but lacks the C-terminal cysteine on the GnRH epitope-containing segment, and has the additional sequence modification of valine substituted for the normal C-terminal residue of ubiquitin. The fusion protein PX552 has a two copy tandem repeat of the GnRH epitope fused to the N-terminus of the native ubiquitin sequence, and also has a two copy tandem repeat of the GnRH epitope inserted at position 35, within a loop region, of the ubiquitin sequence, as with PX546.



## No. 8 Materials & Methods

### Construction of PX546 expression vector

The PX546 ubiquitin fusion protein has the GnRH related epitope sequence QHWSYGLRPGQHWSYGLRPG (SEQ ID NO: 26), inserted into position 35 within the native ubiquitin protein sequence. A genetic construct encoding this sequence was made using synthetic oligonucleotides and methods described in Example 1, and assembled within an expression vector. In brief the pDSub vector was modified to allow insertion of a synthetic oligonucleotide sequence into an Bsm FI and Xcm I cut vector. The synthetic oligonucleotides were ligated into the cut vector. This resulted in a DNA sequence encoding an N-terminal portion of the ubiquitin protein followed by the tandem repeat of the GnRH epitope (SEQ ID NO: 26), followed by the remaining C-terminal sequence of the ubiquitin protein. This placement of the GnRH epitopes within a loop region of the ubiquitin molecule should constrain the epitope structure based on the folding of the ubiquitin protein. Once assembled, the construct was transformed into DH5 $\alpha$  as previously described to generate the *E. coli* expression strain for production and isolation of the PX546 ubiquitin fusion protein. Positive transformants were identified by PCR and then analyzed for expression of the PX546 protein by SDS-PAGE analysis of cell lysates followed by coomassie staining. Re-isolated expression constructs from clones expressing PX546 were then sequenced to confirm receipt of intact constructs. Upon verification, clones were grown under conditions of fermentation and induced to produce PX546 protein, for use in subsequent immunizations, described in detail below.

### Production of PX546 Protein

PX546 expressing clones were fermented in 2X YT without glucose, 100  $\mu$ g/mL ampicillin at 30°C. Fermentation was initiated using an overnight culture

-49-

grown in LB, 100  $\mu$ g/mL ampicillin at 30°C. The culture was grown to an OD<sub>600nm</sub> of 0.5 at which time the culture was induced by addition of IPTG to 0.28 mg/l. The culture was incubated for 1.5 to 2 hours and then harvested. The harvested cell paste was resuspended in 4 mL, of 20 mM Hepes (pH 8.0), 0.5 mM EDTA, 1 mM PMSF, 10  $\mu$ M leupeptin, with an additional 1  $\mu$ M pepstatin per gram of cell pellet, and then lysed by sonication. The lysate was clarified by centrifugation at 20,000 x g, 60 min, 4°C and 0.45  $\mu$ m filtration.

The PX546 protein was isolated from the lysate by SP Sepharose HP ion exchange chromatography, using a column buffered with 20 mM Hepes (pH 8.0), 1 mM DTT, 1 mM EDTA, using a 4 column volume 0 - 0.4 M NaCl gradient elution at a flow rate of 1 mL/min. Peak product fractions were concentrated using a 10,000 MW cut-off membrane, generating purified protein ready for use in immunization.

#### Construction of PX548 and PX549 Expression Vectors

The PX548 ubiquitin fusion protein has the sequence, QHWSYGLRPGQHWSYGLRPGQHWSYGLRPGC (SEQ ID NO: 34) (four consecutive copies of the GnRH epitope) fused to the C-terminal amino acid of ubiquitin. A genetic construct encoding this fusion protein was made using synthetic oligonucleotides, and assembled in an expression vector by methods described in Example 1. In brief, oligonucleotides were kinased, annealed and ligated, followed by PAGE analysis. The assembled oligos were then subjected to PCR to generate the final gene fragment which was then digested with Afl II + Pst I and ligated into the pDSUB expression vector for transformation into *E. coli*. This resulted in a gene sequence encoding ubiquitin followed by the four copies of the GnRH epitope and a C-terminal cysteine.

The PX549 ubiquitin fusion protein was constructed as described for PX548 with the omission of the C-terminal cysteine on the GnRH sequence, and the

-50-

substitution of valine for the normal C-terminal residue of ubiquitin. These vectors were independently transformed into DH5 $\alpha$  as previously described to generate the respective *E. coli* expression strains for production and isolation of the ubiquitin fusion proteins. The transformants were screened by PCR and positive transformants were analyzed for expression of the PX548 or PX549 fusion protein by SDS-PAGE of cell extracts. Positive clones were then further subjected to sequencing to verify receipt of intact constructs and were then subjected to fermentation to produce protein for use in the immunizations described below.

#### Production of PX548 and PX549 protein

A 10 L fermentation of the *E. coli* expression strain for either PX548 or PX549 was performed using 2X YT without glucose, 100  $\mu$ g/mL ampicillin, starting from a 500 mL overnight culture. The fermentation was grown at 37°C to OD<sub>600</sub> 5.0, induced with 1 mM IPTG, and grown 2 additional hrs (to OD 11.0). This produced approximately 169 g cell paste. 25 g of harvested cell paste was lysed by sonication in 4 mL/g 20 mM Hepes (pH 8.0), 1 mM DTT, 1 mM EDTA, 1 mM PMSF, 10  $\mu$ M leupeptin, 1  $\mu$ M pepstatin. The lysate was clarified by centrifugation at 20,000 x g, 60 min, 4°C and 0.45  $\mu$ m filtration.

The PX548 fusion protein was isolated from the cell lysate by SP Sepharose HP ion exchange, 20 mM Hepes (pH 8.0), 1 mM DTT, 1 mM EDTA, using a 4 column volume 0 - 0.4 M NaCl gradient elution at a flow rate of 1 mL/min. Peak product fractions contained 0.294 g of protein based on bicinchoninic acid (BCA) protein determination. SDS-PAGE and coomassie staining of the products indicated approximately 85% pure PX548. This material was either a) concentrated using a 10,000 MW cut-off membrane to contain 4 mg of GnRH epitope in 400  $\mu$ L for MBS conjugation to ovalbumin to produce PX 548-OVA, MBS 2 (discussed below), or b) further purified by reverse phase HPLC and lyophilized before MBS conjugation to

-51-

ovalbumin, to produce PX 548-OVA, MBS1 (discussed below).  
HPLC purification of PX548 was accomplished using a Vydac  
218TP510 1.0 cm x 25 cm C<sub>18</sub> reverse phase column with a 6  
min 30-38% acetonitrile H<sub>2</sub>O 0.1% trifluoroacetic acid  
5 (TFA), acetonitrile 0.1% TFA gradient at a flow rate of  
5.00 mL/min. The ion exchange fraction fusion protein  
was diluted with two volumes of H<sub>2</sub>O 0.1% TFA prior to  
injection on the HPLC column. The retention time of the  
non-overloaded product peak was 5.475 min. The PX548  
10 HPLC fraction was lyophilized and stored desiccated at  
20°C. PX549 was produced using similar methods,  
generating similar yields.

MBS conjugation of PX548 to ovalbumin

A 20:1 molar ratio of MBS to ovalbumin was used in  
15 the conjugation. 22.4 µL of 25 mg/mL *m*-maleimidobenzoyl-  
*N*-hydroxysuccinimide ester (MBS, Pierce) in dimethyl  
formamide, was slowly added to 600 µL of 6.67 mg/mL  
ovalbumin (4 mg, Imject, Pierce). The pH of the reaction  
was adjusted to 5.0 by the addition of 12 M HCl, and the  
20 reaction was allowed to proceed for 1 hr at room  
temperature before removal of reaction precipitate by  
microcentrifugation, and isolation of the MBS-derivatized  
ovalbumin using a NAP 10 (Pharmacia) G-25 size exclusion  
desalting column with 0.1 M 4-morpholine ethane-sulfonic  
25 acid (MES) (pH 4.7), 0.15 M NaCl. The HPLC purified  
PX548 was immediately added to the MBS-ovalbumin, the pH  
was adjusted to 7.0 with 5 M NaOH, and the reaction was  
allowed to proceed at room temperature for 6 hrs or  
overnight. The HPLC purified PX548 was prepared for  
30 addition to the above reaction mixture by dissolving 11.1  
mg of lyophilized PX548 (4 mg of GnRH epitope) in 250 µL  
H<sub>2</sub>O (sonication was required for solubilization). The  
conjugated sample produced (PX548-OVA, MBS,1) was  
concentrated to 430 µL and used in immunizations.  
35 22.1 mg ion exchange purified PX548 (8 mg of GnRH  
epitope) was concentrated to 400 µL and the pH adjusted  
to pH 5 prior to addition to 4 mg of MBS-derivatized

-52-

ovalbumin. The 1.5 mL conjugation reaction product (PX548-OVA, MBS,2) was used in immunizations without further concentration.

EDC conjugation of PX549 to ovalbumin

5        4.40 mg of lyophilized PX549 (corresponding to 1.6 mg GnRH epitope) was dissolved in 440  $\mu$ L H<sub>2</sub>O, and then added to 106.7  $\mu$ L of 15.0 mg/mL ovalbumin (1.6 mg, Imject, Pierce), and the pH was adjusted to 4.5-5.0 by the addition of 12 M HCl. 7.5 mg of solid 1,ethyl-3-[3-  
10    di-methyl-amino-propyl] carbodiimide hydrochloride (EDC) was added to the reaction, and the reaction was mixed and allowed to proceed for 2 hrs at room temperature. The small amount of precipitate produced by the reaction was spun down by microcentrifugation, and the supernatant was  
15    added to 1 mL of H<sub>2</sub>O in a centricon 10; 10,000 MW cut-off concentrator. The reaction product was buffer exchanged by three successive concentrations and dilutions with 1.5 mL H<sub>2</sub>O, giving a final retentate volume of 365  $\mu$ L. This material was ready for use in the immunization described  
20    below.

Construction of PX552 expression vector

This ubiquitin fusion protein contains two copies of the sequence QHWSYGLRPGQHWSYGLRPG (SEQ ID NO: 26), one  
25    at the N-terminus of the fusion protein, fused to residue 1 of ubiquitin, and the other inserted between residues 35 and 36 of the native ubiquitin sequence. A genetic construct expressing the precursor to this fusion protein was made using synthetic oligonucleotides and methods described in Example 1 to generate an expression vector  
30    containing a first ubiquitin gene linked to a gene sequence encoding QHWSYGLRPGQHWSYGLRPG (SEQ ID NO: 26) followed by a gene sequence encoding a sequence as described for PX546. This resulted in a gene sequence encoding a first ubiquitin protein linked to  
35    QHWSYGLRPGQHWSYGLRPG (SEQ ID NO: 26) followed by a an N-terminal portion of ubiquitin (amino acids 1-35) followed

-53-

by the tandem repeat of the GnRH epitope, followed by the remaining C-terminal sequence of the ubiquitin. Expression and processing of this construct results in a fusion protein which has GnRH epitopes both at the N-terminus and within a loop region of an ubiquitin molecule, which should constrain the internal epitope structure based on the folding of the ubiquitin. This coding sequence, contained within the expression construct pDSUb, was transfected into an *E. coli* host strain which contained an expression construct for the UBPl gene. Co-expression of UBPl with the ubiquitin fusion protein resulted in the cleavage of the C-terminal protein from the N-terminal intact native ubiquitin within the host *E. coli*. Thus, this expression results in the cleavage of the first or N-terminal ubiquitin from the fusion releasing an intact ubiquitin and the PX552 ubiquitin fusion protein.

#### Production of PX552 protein

The *E. coli* expression strain, containing expression vectors for both UBPl and the ubiquitin fused to an ubiquitin fusion protein, was grown in a 1 L shaker flask in 2X YT without glucose, 100 µg/mL ampicillin, from a 10 mL overnight culture at 37°C to OD<sub>600</sub> >3.0. UBPl and fusion protein expression was induced with 1 mM IPTG and the culture was grown for an additional 2 hrs post induction at 37°C. Cells were collected by centrifugation, resuspended in 50 mM Tris pH 8.0, 5 mM DTT, 1 mM PMSF, and lysed by sonication. The pellet obtained from centrifugation at 14,200 x g, 60 min, 4°C, was washed by resuspension in lysis buffer and recentrifuged to yield 6.0 g of an inclusion body fraction which contained the PX552 fusion protein. The fusion protein was solubilized by the slow addition of 6 M urea to the inclusion body fraction with stirring overnight, followed by centrifugation at 14,200 x g, 60 min, 4°C. The resolubilized fusion protein present in the supernatant was dialyzed overnight against 4 L of

-54-

phosphate buffered saline (PBS) (pH 7.4), which resulted in precipitation of the PX552 product. The precipitate was collected by centrifugation and resuspended in PBS to yield 636 mg of protein as determined by BCA protein determination, which was approximately 80% PX552 as  
5 determined by SDS-PAGE and coomassie staining. 6.4 mg/mL of the heterogeneous suspension was used for animal immunizations performed in Example 9.

PX552 was prepared for immunizations performed in  
10 Example 10 by column fractionation of resolubilized inclusion bodies. 3 mL of the 6 M urea resolubilized PX552 inclusion body fraction, 20.3 mg/mL, 60.9 mg total protein (by BCA assay), was loaded onto a 1 cm x 50 cm column packed with Sephadex G-15 (38.5 mL bed volume)  
15 equilibrated with 25 mM Tris (pH 8.0). The flow rate was 0.8 mL/min (1.0 cm/min). The peak fractions contained considerably less protein, 12.8 mg total, compared to the load fraction, and the protein purity from size exclusion was not improved. The best PX552 G-15 fraction was  
20 concentrated from 4.0 mL (1.15 mg GnRH epitope) to 330  $\mu$ L by centricon 10, with removal of formed precipitate by microcentrifugation.

#### No. 9

#### Immunocastration of pigs with Ubiquitin-GnRH fusion 25 protein

Immature pigs were immunized with ubiquitin GnRH fusion proteins in an attempt to generate an antibody response to the self protein GnRH. Generation of an antibody response to endogenous GnRH is expected to  
30 produce an overall reduction in testis growth and development of the immunized animal, a process termed immunocastration.

The results presented in Table 3 indicate that the immunization with ubiquitin fusion proteins PX548 or  
35 PX552 induced an immune response to GnRH, as determined by reduced testis size. Immunization with the ubiquitin fusion protein PX552, which contained GnRH epitope both

-55-

at the N-terminus and within the ubiquitin structure, produced the most significant response. All four dose amounts of PX552 significantly decreased the average testis weight by the end of the trial, as compared to  
 5 testis weight of control pigs and pigs immunized with other ubiquitin-GnRH epitope fusion proteins.

Table 3: Immunocastration of pigs with Ubiquitin fusion protein.

Treatment	Dose (ug)	Testis wt., mean(g)
PX548-OVA, MBS,1	500	304
	250	301.5
	100	287
	50	252
	25	358.5
PX552	500	61
	250	65.5
	100	57
	50	77.5
	25	81
PX552	500	54
	250	225.5
	100	106
	50	32.5
	25	275.5
PX548-OVA, MBS,2	500	132
	250	65.5
	100	133
	50	224.5
	25	283
Control no antigen	0	302
	0	277.5
	0	335*

One Pig

Data points are an average of two pigs (four testes) unless otherwise indicated.



-56-

No. 9 Materials & Methods:Immunization

The recombinant fusion protein immunogens were prepared as described in Example 8 and placed in vials for use in immunization. Fusion protein amounts were normalized for GnRH epitope content. Each vial contained an amount of fusion protein that corresponded to 4 mg GnRH epitope in waterphase. Water-in-oil emulsions were prepared using Specol, a light mineral oil consisting of two detergents, as the oil phase (Bokhout et al., *Veterinary Immunology and Immunopathology* 2: 491-500 (1981)). Five parts (v/v) Specol were brought into a 10 mL glass vessel and the waterphase (4 parts v/v) consisting of the antigen in PBS was slowly added while the emulsion was stirred with an Ultra Turrax (Janke and Kunkel, Staufen, Germany). After addition of the waterphase, the emulsion was stirred for half a minute at the same rotation speed (15000 rpm). Emulsions were stored overnight at 4°C to check stability and were administered to the animals the next day.

Male piglets of approximately 11 weeks of age were used. The crossbred piglets were housed in half slatted pens and were given *ad libitum* access to feed and water. Piglets were randomly assigned to the treatments.

All animals were injected with either 2 mL emulsion containing the antigen, or an emulsion made without antigen as a control. All compounds were tested in 5 different dosages, containing 500, 250, 100, 50 or 25 µg GnRH epitope.

Injections were administered intramuscularly in the neck at the start of the experiment (day 0) and 7 weeks post initial vaccination (wpv). The animals were sacrificed at 14 wpv.

After sacrifice, testes were removed, dissected free of epididymes and weighed. Testes weights were recorded as an average of both testes of each animal.

No. 10Ubiquitin-GnRH fusion protein immunization of rabbits

Immature rabbits were immunized with ubiquitin GnRH fusion proteins in an attempt to generate an antibody response to the self protein GnRH which results in immunocastration of the recipient animal. Upon immunization, the rabbits were monitored for the generation of antibodies specific for GnRH and also for testis development. This example shows the induction of an antibody response to the self protein GnRH and the physiological consequences of this on testis size.

The results presented in Table 4 clearly demonstrate that the ubiquitin fusion proteins can function as immunogens for self antigens. By 6 wpv, rabbits immunized with several of the fusion proteins had generated a humoral immune response towards GnRH. There was a clear relationship between antibody titer and final testis weight. Rabbits with GnRH antibody titers higher than 3.1 showed significantly reduced testis weights, indicating that the immune response was of a high enough magnitude to effect testis growth and development via immunocastration. Rabbits that were not immunocastrated had antibody titers lower than 1.8.

Final testis weights of the immunized animals are listed in Table 4. Treatments with the following antigens PX548-OVA, MBS; PX549-OVA, EDC; and PX552 were fully effective, as both test rabbits immunized with these compounds had low testis weight compared to that of control animals. Immunization with non-conjugated PX548 and PX546 produced mixed results; in each case; a significant GnRH antibody titer was only observed in one of two animals in each case. However, these titers also correlated with low testes weight. Immunization with non-conjugated PX549 elicited little if any immune response towards GnRH. Although a weak antibody response was detected in one animal, rabbits treated with PX549 showed normal testis development, with testis weights similar to that of control rabbits.

Table 4: Effect of immunization with different ubiquitin-GnRH compounds on testis weight and GnRH antibody titer induced by immunization with these compounds.

Treatment	Rabbit number	Mean testis weight (mg)	GnRH antibody titer at 6 wpv
PX548-OVA, MBS,1	430	267	4.1
	431	307	3.7
PX549-OVA, EDC	432	321	3.7
	433	475	3.8
PX548	434	483	3.1
	435	2349	<1.5
PX549	436	2311	1.8
	437	2162	<1.5
PX552	429	359	3.8
	439	310	3.8
PX546	440	2104	1.6
	441	336	2.7
No antigen	448	2423	<1.5
	449	2614	<1.5

No. 10 Materials & MethodsImmunizations

The fusion proteins in a water phase were emulsified with Specol (Bokhout et al., *Veterinary Immunology and Immunopathology* 2: 491-500 (1981)) to a stable water-in-oil-emulsion. The emulsions were prepared using an Ultra Turrax (Janke and Kunkel, Staufen, Germany) with a stirring bar. Five parts (v/v) of the oil phase Specol was brought into a 10 mL glass vessel and the water phase (4 parts v/v), consisting of the GnRH compound in milli Q water, was slowly added while the mixture was stirred. After addition of the water phase, the mixture was stirred for half a minute at the same rotation speed (15,000 rpm). Emulsions were stored overnight at 4°C to verify stability and were administered to the animals the following day.

This experiment used 18 male rabbits which were individually housed and were given *ad libitum* access to feed and water.

Animals were immunized at approximately 10 weeks of age with a booster immunization administered at 4 wpv. Each rabbit received 200 µg the ubiquitin GnRH fusion protein, administered in 2 mL Specol emulsion. The 2 mL emulsion was divided into 4 samples of 0.5 mL, of which 2 of the samples were injected subcutaneously in the back region and 2 of the samples were injected intramuscularly in the hindlegs.

Blood samples were taken via puncture of the ear vein at day 0, 4 wpv, 6 wpv and 9 wpv. Blood samples were kept overnight at 4°C and the next day serum was obtained by centrifugation (1,500 g, 15 min). Serum samples were stored at -20°C until assayed. The animals were sacrificed at 9 wpv, testes were removed, dissected free of epididymis, and weighed. Testis weights were recorded as an average of both testes.

-60-

The presence of antibodies to GnRH was determined by ELISA

GnRH was coated in the wells of a microtiterplate using glutaraldehyde (GDA). GDA was coated to the surface of the wells by incubation with 0.2% GDA in 0.1 M phosphate buffer (pH 5) for 4 hours at room temperature. Plates were rinsed 3 times for 10 minutes with 0.1 M phosphate buffer (pH 8). To coat the wells, one microgram peptide in 100  $\mu$ l 0.1 M phosphate buffer (pH 8) was added to each well and incubated for 3 hours at 37°C. Plates were stored at -20°C until used. Thawed plates were rinsed 3 times for 10 minutes with 8.2 g/L NaCl, 1.15 g/L  $\text{Na}_2\text{HPO}_4 \cdot 2\text{H}_2\text{O}$ , 0.20 g/L  $\text{NaH}_2\text{PO}_4 \cdot 2\text{H}_2\text{O}$ , 0.5 mL/L of Tween 80 in milli-Q water.

Serial dilutions of serum were incubated with the coated GnRH for 1 hour at 25°C. Wells were then rinsed 3 times for 10 minutes each rinse. Swine-anti-rabbit IgG coupled to horseradish peroxidase (Dako, Glostrup, Denmark) was introduced as secondary antibody and incubated for 1 hour. ABTS™ (2,2'-azino-di-[3-ethyl benzthiazoline sulfonate] di-imonian salt crystals, Boehringer, Mannheim, Germany) ((250  $\mu$ L (2 g/100 mL) in 10 mL substrate buffer to which 20  $\mu$ L  $\text{H}_2\text{O}_2$  (3% solution) had been added) was added to the wells as substrate. Absorption was measured at 405 nm. Antibody titers are the -log(dilution factor) which gives a signal 4X the background. For example, titer 4.0, means an OD 4X as high as the background at a 10, 000 fold dilution of the serum, e.g. 1/10,000.

-61-

CLAIMS

1. A fusion protein comprising a heat shock protein fused to a single epitope-containing segment, the epitope-containing segment comprising two or more identical self-epitopes.
2. The fusion protein of Claim 1 wherein the heat shock protein is ubiquitin and the fusion protein is a ubiquitin fusion protein.
3. The ubiquitin fusion protein of Claim 2 wherein the epitope-containing segment is fused to ubiquitin at a fusion site selected from the group consisting of the N-terminus, the C-terminus and an internal fusion site.
4. The ubiquitin fusion protein of Claim 2 wherein the N-terminal residue of ubiquitin is a residue other than methionine, and the N-terminal residue other than methionine is fused to the C-terminal residue of a second, unmodified ubiquitin protein.
5. The ubiquitin fusion protein of Claim 2 wherein the N-terminal residue of ubiquitin is a residue other than methionine, and the N-terminal residue other than methionine is fused to the C-terminal residue of a C-terminal ubiquitin subdomain competent to specify cleavage by a ubiquitin-specific protease between the C-terminal residue of the C-terminal ubiquitin subdomain and the N-terminal residue other than methionine.

-62-

6. The ubiquitin fusion protein of Claim 5 wherein at least one epitope-containing segment is positioned between the C-terminal residue of the C-terminal ubiquitin subdomain and the N-terminal residue other than methionine, and the C-terminus of the C-terminal subdomain is modified to inhibit cleavage by a ubiquitin-specific protease.
7. The ubiquitin fusion protein of Claim 2 which is post-translationally modified by the addition of fatty acids to enhance immunogenicity.
8. The ubiquitin fusion protein of Claim 2 wherein the epitope-containing segment contains from about 2 to about 30 self-epitopes.
9. The ubiquitin fusion protein of Claim 2 wherein the identical self-epitopes are B-cell epitopes.
10. The ubiquitin fusion protein of Claim 2 wherein the identical self-epitopes are T-cell epitopes.
11. The ubiquitin fusion protein of Claim 2 wherein the identical self-epitopes are structural mimics of biomolecules.
12. The ubiquitin fusion protein of Claim 2 wherein the identical self-epitopes represent epitopes from the proteins selected from the group consisting of gonadotropin releasing hormone, tumor necrosis factor, immunoglobulins, chorionic gonadotrophin, inhibin, growth hormones and sperm proteins.
13. The ubiquitin fusion protein of Claim 2 wherein the identical self-epitopes are gonadotropin releasing hormone epitopes.

-63-

14. The ubiquitin fusion protein of Claim 13 wherein the epitope-containing segment is comprised of amino acids QHWSYGLRPGQHWSYGLRPG (SEQ ID NO: 26), and is inserted between position 35 and 36 of ubiquitin.
15. The ubiquitin fusion protein of Claim 13 wherein the epitope-containing segment is comprised of amino acids QHWSYGLRPGQHWSYGLRPGQHWSYGLRPGQHWSYGLRPGC (SEQ ID NO: 34) and is fused via its N-terminal amino acid to the C-terminal residue of ubiquitin, the ubiquitin fusion protein being cleavable by a ubiquitin specific protease.
16. The ubiquitin fusion protein of Claim 15 which is further conjugated to an immunogenic carrier protein.
17. The ubiquitin fusion protein of Claim 2 wherein the internal fusion sites comprises a region of ubiquitin linking two domains of secondary structure, the two domains of secondary structure being selected from the group consisting of  $\beta$ -strand and  $\alpha$ -helix.
18. The ubiquitin fusion protein of Claim 2 wherein the epitope-containing segment is fused to the C-terminus of ubiquitin and the C-terminus of ubiquitin is modified to inhibit cleavage of the ubiquitin fusion protein by a ubiquitin-specific protease.
19. The ubiquitin fusion protein of Claim 18 wherein the C-terminus of ubiquitin is modified at amino acid 76.



-64-

20. The ubiquitin fusion protein of Claim 19 wherein the modification at amino acid 76 of ubiquitin is a substitution of an amino acid selected from the group consisting of alanine, valine, and cysteine for the wild-type glycine amino acid residue.
21. The ubiquitin fusion protein of Claim 20 wherein the substituted amino acid is valine.
22. The ubiquitin fusion protein of Claim 21 wherein the epitope-containing segment comprises the amino acids sequence QHWSYGLRPGQHWSYGLRPGQHWSYGLRPGQHWSYGLRPG (SEQ ID NO: 35).
23. The ubiquitin fusion protein of Claim 22 which is further conjugated to an immunogenic carrier protein.
24. A fusion protein comprising a heat shock protein fused to two or more non-contiguous epitope-containing segments, each epitope-containing segment comprising one or more identical or non-identical self-epitopes.
25. The fusion protein of Claim 24 wherein the heat shock protein is ubiquitin and the fusion protein is a ubiquitin fusion protein.
26. The ubiquitin fusion protein of Claim 25 wherein the non-contiguous epitope-containing segments are fused to ubiquitin at fusion sites selected from the group consisting of the N-terminus, the C-terminus and internal fusion sites.

-65-

27. The ubiquitin fusion protein of Claim 25 wherein the N-terminal residue of ubiquitin is a residue other than methionine, and the N-terminal residue other than methionine is fused to the C-terminal residue of a second, unmodified ubiquitin protein.
28. The ubiquitin fusion protein of Claim 25 wherein the N-terminal residue of ubiquitin is a residue other than methionine, and the N-terminal residue other than methionine is fused to the C-terminal residue of a C-terminal ubiquitin subdomain competent to specify cleavage by a ubiquitin-specific protease between the C-terminal residue of the C-terminal ubiquitin subdomain and the N-terminal residue other than methionine.
29. The ubiquitin fusion protein of Claim 28 wherein at least one epitope-containing segment is positioned between the C-terminal residue of the C-terminal ubiquitin subdomain and the N-terminal residue other than methionine, and the C-terminus of the C-terminal subdomain is modified to inhibit cleavage by a ubiquitin-specific protease.
30. The ubiquitin fusion protein of Claim 25 which is post-translationally modified by the addition of fatty acids to enhance immunogenicity.
31. The ubiquitin fusion protein of Claim 25 wherein the epitope-containing segments contain from about 1 to about 30 self-epitopes.
32. The ubiquitin fusion protein of Claim 25 wherein one epitope-containing segment contains at least one epitope which is a B-cell epitope and one epitope which is a T-cell epitope.

-66-

33. The ubiquitin fusion protein of Claim 25 wherein one epitope-containing segment contains at least two epitopes which are B-cell epitopes.
34. The ubiquitin fusion protein of Claim 25 wherein one epitope-containing segment contains at least two epitopes which are T-cell epitopes.
35. The ubiquitin fusion protein of Claim 25 wherein one or more self-epitopes contained within the epitope-containing segments are structural mimics of biomolecules.
36. The ubiquitin fusion protein of Claim 26 wherein one or more self-epitopes contained within the epitope-containing segments represent self-epitopes from the group of proteins selected from the group consisting of gonadotropin releasing hormone, tumor necrosis factor, immunoglobulins, chorionic gonadotrophin, inhibin, growth hormones and sperm proteins.
37. The ubiquitin fusion protein of Claim 36 wherein one or more self-epitopes contained within the epitope-containing segments represent epitopes from gonadotropin releasing hormone.
38. The ubiquitin fusion protein of Claim 37 wherein there are two epitope-containing segments, each comprising two identical self-epitopes.

-67-

39. The ubiquitin fusion protein of Claim 38 wherein the first self-epitope-containing segment is fused to the C-terminal residue of ubiquitin via its N-terminal residue, and the second self-epitope-containing segment is fused at an internal fusion site which comprises regions of ubiquitin linking two domains of secondary structure selected from the group consisting of  $\beta$ -strand and  $\alpha$ -helix.
40. The ubiquitin fusion protein of Claim 39 wherein the second epitope-containing segment is located between position 35 and 36 of ubiquitin.
41. The ubiquitin fusion protein of Claim 40 wherein the epitope-containing segments comprise the amino acid sequence: QHWSYGLRPGQHWSYGLRPG (SEQ ID NO: 26).
42. The ubiquitin fusion protein of Claim 41 wherein the N-terminus of the N-terminal epitope-containing segment is further fused the C-terminal residue of a second ubiquitin protein, the ubiquitin fusion protein being cleavable from the first ubiquitin protein by a ubiquitin specific protease.
43. The ubiquitin fusion protein of Claim 26 wherein the internal fusion sites comprise regions of ubiquitin linking two domains of secondary structure, the two domains of secondary structure being selected from the group consisting of  $\beta$ -strand and  $\alpha$ -helix.
44. The ubiquitin fusion protein of Claim 43 wherein the internal fusion site is between residue 35 and 36 of ubiquitin.

-68-

45. The ubiquitin fusion protein of Claim 46 wherein one epitope-containing segment comprises a single B-cell epitope or a plurality of identical or non-identical B-cell epitopes and a second epitope-containing segment comprises a single T-cell epitope or a plurality of identical or non-identical T-cell epitopes.
46. The ubiquitin fusion protein of Claim 26 wherein at least one epitope-containing segment is fused to the C-terminus of ubiquitin and the C-terminus of ubiquitin is modified to inhibit cleavage of the ubiquitin fusion protein by a ubiquitin-specific protease.
47. The ubiquitin fusion protein of Claim 46 wherein the C-terminus of ubiquitin is modified at amino acid 76.
48. The ubiquitin fusion protein of Claim 47 wherein the modification at amino acid 76 of ubiquitin is a substitution of an amino acid selected from the group consisting of alanine, valine, and cysteine for the wild-type glycine amino acid residue.
49. A fusion protein comprising a heat shock protein fused to a single epitope-containing segment comprising two or more identical or non-identical self-epitopes, the epitope-containing segments being fused to the heat shock protein at fusion sites selected from the group consisting of the N-terminus and an internal fusion site.
50. The fusion protein of Claim 49 wherein the heat shock protein is ubiquitin and the fusion protein is a ubiquitin fusion protein.

-69-

51. The ubiquitin fusion protein of Claim 50 wherein the single epitope-containing segment contains from about 2 to about 30 identical or non-identical self-epitopes.
52. The ubiquitin fusion protein of Claim 50 wherein the N-terminal residue of ubiquitin is a residue other than methionine, and the N-terminal residue other than methionine is fused to the C-terminal residue of a second, unmodified ubiquitin protein.
53. The ubiquitin fusion protein of Claim 50 wherein the N-terminal residue of ubiquitin is a residue other than methionine, and the N-terminal residue other than methionine is fused to the C-terminal residue of a C-terminal ubiquitin subdomain competent to specify cleavage by a ubiquitin-specific protease between the C-terminal residue of the C-terminal ubiquitin subdomain and the N-terminal residue other than methionine.
54. The ubiquitin fusion protein of Claim 53 wherein at least one epitope-containing segment is positioned between the C-terminal residue of the C-terminal ubiquitin subdomain and the N-terminal residue other than methionine, and the C-terminus of the C-terminal subdomain is modified to inhibit cleavage by a ubiquitin-specific protease.
55. The ubiquitin fusion protein of Claim 50 which is post-translationally modified by the addition of fatty acids to enhance immunogenicity.
56. The ubiquitin fusion protein of Claim 50 wherein the epitope-containing segment contains at least one B-cell and one T-cell epitope.

-70-

57. The ubiquitin fusion protein of Claim 50 wherein the epitope-containing segment contains at least two B-cell epitopes.
58. The ubiquitin fusion protein of Claim 50 wherein the epitope-containing segment contains at least two T-cell epitopes.
59. The ubiquitin fusion protein of Claim 50 wherein the epitope-containing segment contains self-epitopes which are structural mimics of biomolecules.
60. The ubiquitin fusion protein of Claim 50 wherein the epitope-containing segment contains at least one self-epitope from proteins selected from the group consisting of gonadotrophin releasing hormone, tumor necrosis factor, immunoglobulins, proteins, chorionic gonadotrophin, inhibin, growth hormones and sperm proteins.
61. The ubiquitin fusion protein of Claim 50 wherein the epitope-containing segment contains self-epitopes from gonadotropin releasing hormone.
62. The ubiquitin fusion protein of Claim 50 wherein the internal fusion site comprises a region of ubiquitin linking two regions of secondary structure selected from the group consisting of  $\beta$ -strand and  $\alpha$ -helix.
63. The ubiquitin fusion protein of Claim 50 wherein the epitope-containing segment contains a single B-cell epitope or a plurality of identical or non-identical B-cell epitopes and a second epitope-containing segment comprises a single T-cell epitope or a plurality of identical or non-identical T-cell epitopes.

-71-

64. A fusion protein comprising a heat shock protein fused to a single epitope-containing segment comprising one or more identical or non-identical self-epitopes, the epitope-containing segment being fused to the heat shock protein at the N-terminus of the heat shock protein.
65. The fusion protein of Claim 64 wherein the heat shock protein is ubiquitin and the fusion protein is a ubiquitin fusion protein.
66. The ubiquitin fusion protein of Claim 65 wherein the epitope-containing segment contains from about 1 to about 30 self-epitopes.
67. The ubiquitin fusion protein of Claim 65 wherein the N-terminal residue of ubiquitin is a residue other than methionine, and the N-terminal residue other than methionine is fused to the C-terminal residue of a second, unmodified ubiquitin protein.
68. The ubiquitin fusion protein of Claim 65 wherein the N-terminal residue of ubiquitin is a residue other than methionine, and the N-terminal residue other than methionine is fused to the C-terminal residue of a C-terminal ubiquitin subdomain competent to specify cleavage by a ubiquitin-specific protease between the C-terminal residue of the C-terminal ubiquitin subdomain and the N-terminal residue other than methionine.
69. The ubiquitin fusion protein of Claim 68 wherein at least one epitope-containing segment is positioned between the C-terminal residue of the C-terminal ubiquitin subdomain and the N-terminal residue other than methionine, and the C-terminus of the C-terminal subdomain is modified to inhibit cleavage by a ubiquitin-specific protease.



-72-

70. The ubiquitin fusion protein of Claim 65 which is post-translationally modified by the addition of fatty acids to enhance immunogenicity.
71. The ubiquitin fusion protein of Claim 65 wherein the epitope-containing segment contains at least one B-cell epitope and one T-cell epitope.
72. The ubiquitin fusion protein of Claim 65 wherein the epitope-containing segment contains at least two B-cell epitopes.
73. The ubiquitin fusion protein of Claim 65 wherein the epitope-containing segment contains at least two T-cell epitopes.
74. The ubiquitin fusion protein of Claim 65 wherein one or more self-epitopes contained within the epitope-containing segment is a structural mimic of a biomolecule.
75. The ubiquitin fusion protein of Claim 65 wherein one or more self-epitopes contained within the epitope-containing segment represent a self-epitope from the group of proteins selected from the group consisting of gonadotropin releasing hormone, tumor necrosis factor, immunoglobulins, chorionic gonadotrophin, inhibin, growth hormones and sperm proteins.
76. The ubiquitin fusion protein of Claim 75 wherein one or more self-epitopes contained within the epitope-containing segment represent a self-epitope from gonadotropin releasing hormone.

-73-

77. The ubiquitin fusion protein of Claim 65 wherein the epitope-containing segment contains a single B-cell epitope or a plurality of identical or non-identical B-cell epitopes and a second epitope-containing segment comprises a single T-cell epitope or a plurality of identical or non-identical T-cell epitopes.
78. A DNA construct encoding the fusion protein of Claim 1, 24, 49, or 64.
79. A DNA construct encoding the fusion protein of Claim 14, 15, 22, 41, or 42.
80. A cell containing a DNA construct encoding the fusion protein of Claim 1, 24, 49, or 64.
81. A cell containing a DNA construct encoding the fusion protein of Claim 14, 15, 22, 41, or 42.
82. A method for stimulating an immune response in an animal, the immune response being directed toward a self-antigen, the method comprising:
  - a) providing a ubiquitin fusion protein comprising ubiquitin fused to one or more contiguous or non-contiguous epitope-containing segments, the epitope-containing segments comprising two or more identical or non-identical self-epitopes; and
  - b) administering the fusion protein of step a) to an animal under conditions appropriate for the stimulation of an immune response.
83. The method of Claim 82 wherein the ubiquitin fusion protein of step a) is conjugated to an immunogenic carrier protein prior to administration.

-74-

84. The method of Claim 82 wherein fusion of the epitope-containing segments to ubiquitin occurs at sites selected from the group consisting of the C-terminus, the N-terminus, and an internal site of ubiquitin.
85. The method of Claim 84 wherein one epitope-containing segment is fused to ubiquitin and the fusion site is the C-terminus of ubiquitin.
86. The method of Claim 85 wherein the epitope-containing segment fused to the C-terminus of ubiquitin is cleavable by a ubiquitin-specific protease.
87. The method of Claim 85 wherein the ubiquitin moiety is modified such that the epitope-containing segment fused to the C-terminus of ubiquitin is non-cleavable by a ubiquitin-specific protease.
88. The method of Claim 84 wherein the self-antigen is a peptide hormone.
89. The method of Claim 88 wherein the peptide hormone is a male-specific or female-specific peptide hormone.
90. The method of Claim 89 wherein the peptide hormone is gonadotropin releasing hormone.
91. The method of Claim 90 wherein the physiological consequences of administration to the animal are substantially similar to the consequences of surgical castration.
92. The method of Claim 91 wherein the animal is a pig.

-75-

93. The method of Claim 90 wherein one epitope-containing segment which comprises the amino acid sequence QHWSYGLRPGQHWSYGLRPG (SEQ ID NO: 26) is fused to ubiquitin between positions 35 and 36 of the ubiquitin amino acid sequence.
94. The method of Claim 90 wherein two non-contiguous epitope-containing segments, each comprising the amino acid sequence QHWSYGLRPGQHWSYGLRPG (SEQ ID NO: 26) are fused to a single ubiquitin molecule, one being fused to the N-terminal amino acid of ubiquitin, the other being fused at an internal site of ubiquitin, the internal site being between residue 35 and 36 of ubiquitin.
95. The method of Claim 87 wherein one epitope-containing segment which comprises the amino acid sequence QHWSYGLRPGQHWSYGLRPGQHWSYGLRPGQHWSYGLRPG (SEQ ID NO: 35) is fused via its N-terminus to the C-terminal residue of ubiquitin.
96. The method of Claim 86 wherein one epitope-containing segment which comprises QHWSYGLRPGQHWSYGLRPGQHWSYGLRPGQHWSYGLRPGC (SEQ ID NO: 34) is fused via its N-terminus to the C-terminal residue of ubiquitin.
97. A method for stimulating an immune response in an animal, the immune response being directed toward a ubiquitin fusion protein, the method comprising:
- a) providing a ubiquitin fusion protein comprising ubiquitin fused to a single epitope-containing segment, the epitope-containing segment comprising two or more identical epitopes;
  - b) administering the fusion protein of step a) to an animal under conditions appropriate for the stimulation of an immune response.

-76-

98. A method for stimulating an immune response in an animal, the immune response being directed toward a ubiquitin fusion protein, the method comprising:
- a) providing a ubiquitin fusion protein comprising ubiquitin fused to two or more non-contiguous epitope-containing segments, each epitope-containing segment comprising one or more identical or non-identical epitopes;
  - b) administering the fusion protein of step a) to an animal under conditions appropriate for the stimulation of an immune response.
99. A method for stimulating an immune response in an animal, the immune response being directed toward a ubiquitin fusion protein, the method comprising:
- a) providing a ubiquitin fusion protein comprising ubiquitin fused to a single epitope-containing segment comprising two or more identical or non-identical epitopes, the epitope-containing segments being fused to ubiquitin at fusion sites selected from the group consisting of the N-terminus and an internal fusion site;
  - b) administering the fusion protein of step a) to an animal under conditions appropriate for the stimulation of an immune response.
100. A method for stimulating an immune response in an animal, the immune response being directed toward a ubiquitin fusion protein, the method comprising:
- a) providing a ubiquitin fusion protein comprising ubiquitin fused to a single epitope-containing segment comprising one or more identical or non-identical epitopes, the epitope-containing segment being fused to ubiquitin at N-terminus of ubiquitin;
  - b) administering the fusion protein of step a) to an animal under conditions appropriate for the stimulation of an immune response.

-77-

101. A method for stimulating an immune response in an animal, the immune response being directed toward a self-antigen, the method comprising:
- a) providing a DNA construct encoding the fusion protein of Claim 1, 24, 49 or 64;
  - b) introducing the DNA construct of step a) into the cells of the animal under conditions appropriate for expression.
102. A method for the identification of antibodies in experimental or diagnostic samples, comprising:
- a) providing a ubiquitin fusion protein selected from the group consisting of ubiquitin fusion proteins described in Claims 1, 24, 49 and 64;
  - b) providing antibodies from an experimental or clinical source;
  - c) forming an incubation mixture comprising the ubiquitin fusion protein of step a) and the antibodies of step b); and
  - d) detecting binding of the antibodies of step b) to the ubiquitin fusion protein of step a).
103. A method for reducing levels of a predetermined endogenous protein in an animal relative to baseline levels, comprising:
- a) providing a ubiquitin fusion protein selected from the group consisting of ubiquitin fusion proteins described in Claim 1, 24, 49 and 64, the ubiquitin fusion protein containing at least one self-epitope representing an epitope from the predetermined endogenous protein; and
  - b) administering the fusion protein of step a) to the animal under conditions appropriate for the stimulation of an immune response.
104. The method of Claim 103 wherein the predetermined endogenous protein is a peptide hormone.

-78-

105. The method of Claim 104 wherein the predetermined endogenous peptide hormone is a male-specific or female-specific peptide hormone.
106. The method of Claim 105 wherein the predetermined endogenous peptide hormone is gonadotropin releasing hormone.
107. The method of Claim 103 wherein the predetermined endogenous protein is tumor necrosis factor.
108. The method of Claim 103 wherein the predetermined endogenous protein is a growth hormone protein.
109. The method of Claim 103 wherein the fusion protein is conjugated to a non-ubiquitin carrier protein.
110. A method for reducing levels of a predetermined endogenous protein in an animal relative to baseline levels, comprising:
  - a) providing a DNA construct encoding a ubiquitin fusion protein selected from the group consisting of ubiquitin fusion proteins described in Claim 1, 24, 49 and 64, the ubiquitin fusion protein containing at least one self-epitope representing an epitope from the predetermined endogenous protein; and
  - b) introducing the DNA construct of step a) into the cells of an animal under conditions appropriate for expression and stimulation of an immune response.
111. The method of Claim 110 wherein the predetermined endogenous protein is a peptide hormone.
112. The method of Claim 111 wherein the predetermined endogenous peptide hormone is a male-specific or female-specific peptide hormone.

-79-

113. The method of Claim 112 wherein the predetermined endogenous peptide hormone is gonadotropin releasing hormone.
114. The method of Claim 110 wherein the predetermined endogenous protein is tumor necrosis factor.
115. The method of Claim 110 wherein the predetermined endogenous protein is a growth hormone protein.
116. The method of Claim 110 wherein the fusion protein is conjugated to a non-ubiquitin carrier protein.



## SEQUENCE LISTING

<110> Proteinix Company

<120> HEAT SHOCK FUSION-BASED VACCINE SYSTEM

<130> IGN-2004WO

<140> NOT YET ASSIGNED

<141> 2000-08-14

<150> 09/026,276

<151> 1998-02-19

<150> US 09/374,721

<151> 1999-08-13

<160> 35

<170> PatentIn Ver. 2.0

<210> 1

<211> 35

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: polypeptide  
antigen

<400> 1

Cys	Thr	Arg	Pro	Asn	Asn	Asn	Thr	Arg	Lys	Ser	Ile	His	Ile	Gly	Pro
1				5				10					15		

Gly	Arg	Ala	Phe	Tyr	Thr	Thr	Gly	Glu	Ile	Ile	Gly	Asp	Ile	Arg	Gln
			20					25					30		

Ala	His	Cys
		35

<210> 2

<211> 15

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: polypeptide

<400> 2  
Lys Arg Ile His Ile Gly Pro Gly Arg Ala Phe Tyr Thr Thr Lys  
1 5 10 15

<220>  
<223> Description of Artificial Sequence: polypeptide antigen

**CyB**

<220>  
<223> Description of Artificial Sequence: PCR primer

<400> 4  
ttaagactgc gtggcggcga ccaggttcac ttccagccgc tgccgccggc 50

```
<210> 5
<211> 37
<212> DNA
<213> Artificial Sequence
```

<220>  
<223> Description of Artificial Sequence: PCR Primer

<400> 5  
tggtgttaaa ctgtctgacg ctctgtaagc ttctgca 37

<210> 6  
<211> 43



<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: PCR primer

<400> 6

gaagcttaca gagcgtcaga cagtttaaca acagccggcg gca

43

<210> 7

<211> 36

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: PCR primer

<400> 7

gcggctggaa gtgaacctgg tcgccgccac gcagtc

36

<210> 8

<211> 50

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: PCR primer

<400> 8

ttaagactgc gtggcgctga ccagggttcac ttccagccgc tgccgccggc

50

<210> 9

<211> 36

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: PCR primer

<400> 9

gcggctggaa gtgaacctgg tcagcgccac gcagtc

36

<210> 10

<211> 55

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: PCR primer

<400> 10  
aagaaatcca catcggtccg ggtcgtgctt tctacaccac catcccgccg gatca 55

<210> 11

<211> 54

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: PCR primer

<400> 11  
atccggcggg atggtggtgt agaaagcacg acccggaccg atgtggattt cttt 54

<210> 12

<211> 33

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: PCR primer

<400> 12  
ttaagactgc gtggcggcat ccacatcggt ccg 33

<210> 13

<211> 29

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: PCR primer

<400> 13  
ggtcgtgctt tctacaccac ctaactgca 29

<210> 14

<211> 34

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: PCR primer

<400> 14  
gtaggtggt gtagaaagca cgaccggac cgat 34

<210> 15  
<211> 20  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: PCR primer

<400> 15  
gtggatgccg ccaacgcagtc

20

<210> 16  
<211> 12  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: polypeptide  
antigen

<400> 16  
Ile His Ile Gly Pro Gly Arg Ala Phe Tyr Thr Thr  
1 5 10

<210> 17  
<211> 19  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: polypeptide  
antigen

<400> 17  
Asp Gln Val His Phe Gln Pro Leu Pro Pro Ala Val Val Lys Leu Ser  
1 5 10 15

Asp Ala Leu

<210> 18  
<211> 22  
<212> PRT  
<213> Artificial Sequence

&lt;220&gt;

<223> Description of Artificial Sequence: polypeptide  
antigen

&lt;400&gt; 18

Lys Glu Asp Val Cys Ala Gln Val His Pro Gln Lys Val Thr Lys Phe  
1 5 10 15Met Leu Cys Ile Pro Pro  
20

&lt;210&gt; 19

&lt;211&gt; 22

&lt;212&gt; PRT

&lt;213&gt; Artificial Sequence

&lt;220&gt;

<223> Description of Artificial Sequence: polypeptide  
antigen

&lt;400&gt; 19

Lys Glu Asp Val Cys Ala Gln Val His Pro Gln Lys Val Thr Lys Phe  
1 5 10 15Met Leu Cys Met Pro Pro  
20

&lt;210&gt; 20

&lt;211&gt; 20

&lt;212&gt; PRT

&lt;213&gt; Artificial Sequence

&lt;220&gt;

<223> Description of Artificial Sequence: polypeptide  
antigen

&lt;400&gt; 20

Lys Glu Cys Ala Gln Val His Pro Gln Lys Val Thr Lys Phe Met Leu  
1 5 10 15Cys Ile Pro Pro  
20

&lt;210&gt; 21

&lt;211&gt; 17

&lt;212&gt; PRT

&lt;213&gt; Artificial Sequence

&lt;220&gt;

<223> Description of Artificial Sequence: polypeptide  
antigen

&lt;400&gt; 21

Lys	Glu	Cys	Ala	Gln	Val	His	Pro	Gln	Lys	Val	Thr	Lys	Phe	Met	Pro
1				5					10					15	

Pro

&lt;210&gt; 22

&lt;211&gt; 31

&lt;212&gt; PRT

&lt;213&gt; Artificial Sequence

&lt;220&gt;

<223> Description of Artificial Sequence: polypeptide  
antigen

&lt;400&gt; 22

Arg	Gly	Gly	Ser	Leu	Arg	Arg	Ser	Ser	Cys	Phe	Gly	Gly	Arg	Met	Asp
1				5					10					15	

Arg	Ile	Gly	Ala	Gln	Ser	Gly	Leu	Gly	Cys	Asn	Ser	Phe	Arg	Tyr
			20					25						30

&lt;210&gt; 23

&lt;211&gt; 11

&lt;212&gt; PRT

&lt;213&gt; Artificial Sequence

&lt;220&gt;

<223> Description of Artificial Sequence: polypeptide  
antigen

&lt;400&gt; 23

Arg	Gly	Gly	Asp	Tyr	Lys	Asp	Asp	Asp	Asp	Lys
1					5					10

&lt;210&gt; 24

&lt;211&gt; 23



&lt;212&gt; PRT

&lt;213&gt; Artificial Sequence

&lt;220&gt;

<223> Description of Artificial Sequence: polypeptide  
antigen

&lt;400&gt; 24

Arg Gly Ala Leu Tyr Thr Lys Val Val His Tyr Arg Lys Trp Ile Lys  
1 5 10 15Asp Thr Ile Val Ala Asn Pro  
20

&lt;210&gt; 25

&lt;400&gt; 25

000

&lt;210&gt; 26

&lt;211&gt; 20

&lt;212&gt; PRT

&lt;213&gt; Artificial Sequence

&lt;220&gt;

<223> Description of Artificial Sequence: polypeptide  
antigen

&lt;400&gt; 26

Gln His Trp Ser Tyr Gly Leu Arg Pro Gly Gln His Trp Ser Tyr Gly  
1 5 10 15Leu Arg Pro Gly  
20

&lt;210&gt; 27

&lt;211&gt; 21

&lt;212&gt; PRT

&lt;213&gt; Artificial Sequence

&lt;220&gt;

<223> Description of Artificial Sequence: polypeptide  
antigen

&lt;400&gt; 27

Asp Asp Pro Lys Thr Gly Gln Phe Leu Gln Gln Ile Asn Ala Tyr Ala  
1 5 10 15

Arg Pro Ser Glu Val  
20

<210> 28  
<211> 10  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: polypeptide  
antigen

<400> 28  
Glu His Trp Ser Tyr Gly Leu Arg Pro Gly  
1 5 10

<210> 29  
<211> 20  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: polypeptide  
antigen

<400> 29  
Glu His Trp Ser Tyr Gly Leu Arg Pro Gly Glu His Trp Ser Tyr Gly  
1 5 10 15

Leu Arg Pro Gly  
20

<210> 30  
<211> 20  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: polypeptide  
antigen

<400> 30  
Glu His Trp Ser Tyr Gly Leu Arg Pro Gly Gln His Trp Ser Tyr Gly  
1 5 10 15

Leu Arg Pro Gly  
20

<210> 31  
<211> 20  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: polypeptide  
antigen

<400> 31  
Gln His Trp Ser Tyr Gly Leu Arg Pro Gly Glu His Trp Ser Tyr Gly  
1 5 10 15

Leu Arg Pro Gly  
20

<210> 32  
<211> 10  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: polypeptide  
antigen

<400> 32  
Gln His Trp Ser Tyr Gly Leu Arg Pro Gly  
1 5 10

<210> 33  
<400> 33  
000

<210> 34  
<211> 41  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: polypeptide  
antigen

&lt;400&gt; 34

Gln His Trp Ser Tyr Gly Leu Arg Pro Gly Gln His Trp Ser Tyr Gly  
 1                      5                      10                      15

Leu Arg Pro Gly Gln His Trp Ser Tyr Gly Leu Arg Pro Gly Gln His  
                     20                      25                      30

Trp Ser Tyr Gly Leu Arg Pro Gly Cys  
                     35                      40

&lt;210&gt; 35

&lt;211&gt; 40

&lt;212&gt; PRT

&lt;213&gt; Artificial Sequence

&lt;220&gt;

<223> Description of Artificial Sequence: polypeptide  
 antigen

&lt;400&gt; 35

Gln His Trp Ser Tyr Gly Leu Arg Pro Gly Gln His Trp Ser Tyr Gly  
 1                      5                      10                      15

Leu Arg Pro Gly Gln His Trp Ser Tyr Gly Leu Arg Pro Gly Gln His  
                     20                      25                      30

Trp Ser Tyr Gly Leu Arg Pro Gly  
                     35                      40

# INTERNATIONAL SEARCH REPORT

International application No.  
PCT/US00/22121

## A. CLASSIFICATION OF SUBJECT MATTER

IPC(7) : A61K 39/00; C12N 15/56, 9/10, 15/00, 5/06  
US CL : 536/24.1; 435/193; 424/193.1; 530/350  
According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

U.S. : 536/24.1; 435/193; 424/193.1; 530/350

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)  
Please See Extra Sheet.

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	EP 0848061 A2 (HOECHST AKTIENGESELLSCHAFT) 17 June 1998 (17-06-98), see full document.	1-23
Y,P	US 6,007,821 A (SRIVASTAVA ET AL) 28 December 1999 (28-12-98), see entire document.	1-23
Y,P	US 5,989,883 A (AU-YOUNG ET AL) 23 November 1999 (23-11-99), see entire document.	1-23
Y	US 5,510,474 A (QUAIL ET AL) 23 April 1996 (23-04-96), see entire document.	1-23

☐ Further documents are listed in the continuation of Box C. ☐ See patent family annex.

* Special categories of cited documents:	*T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
*A* document defining the general state of the art which is not considered to be of particular relevance	*X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
*E* earlier document published on or after the international filing date	*Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
*L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	*A* document member of the same patent family
*O* document referring to an oral disclosure, use, exhibition or other means	
*P* document published prior to the international filing date but later than the priority date claimed	

Date of the actual completion of the international search  
10 OCTOBER 2000

Date of mailing of the international search report  
06 DEC 2000

Name and mailing address of the ISA/US  
Commissioner of Patents and Trademarks  
Box PCT  
Washington, D.C. 20231  
Facsimile No. (703) 305-3230

Authorized officer  
ROBERT A. ZEMAN  
Telephone No. (703) 308-0196

# INTERNATIONAL SEARCH REPORT

International application No.  
PCT/US00/22121

## Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This international report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☐ Claims Nos.:  
because they relate to subject matter not required to be searched by this Authority, namely:
2. ☐ Claims Nos.:  
because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:
3. ☐ Claims Nos.:  
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

## Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

Please See Extra Sheet.

1. ☐ As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☒ No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

1-23

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.  
☐ No protest accompanied the payment of additional search fees.

## INTERNATIONAL SEARCH REPORT

International application No.  
PCT/US00/22121

### B. FIELDS SEARCHED

Electronic data bases consulted (Name of data base and where practicable terms used):

STN; MEDLINE; CAPLUS; BIOSIS; WEST

fusion protein; ubiquitin; self epitope; heat shock protein; hsp; c-terminus; n-terminus

### BOX II. OBSERVATIONS WHERE UNITY OF INVENTION WAS LACKING

This ISA found multiple inventions as follows:

This application contains the following inventions or groups of inventions which are not so linked as to form a single inventive concept under PCT Rule 13.1. In order for all inventions to be searched, the appropriate additional search fees must be paid.

Group I, claim(s) 1-23, drawn to fusion proteins comprising a heat shock protein to a single epitope-containing segment, the epitope-containing segment comprising two or more identical self-epitopes.

Group II, claim(s) 24-48, drawn to fusion proteins comprising a heat shock protein fused to two or more non-contiguous epitope-containing segments, each epitope containing segment comprising one or more identical or non-identical self-epitopes.

Group III, claim(s) 49-63, drawn to fusion proteins comprising a heat shock protein fused to a single epitope-containing segment comprising two or more identical or non-identical self-epitopes.

Group IV, claim(s) 64-77, drawn to fusion proteins comprising a heat shock protein fused to a single epitope-containing segment comprising one or more identical or non-identical self-epitopes fused to the heat shock protein at the N-terminus of said heat shock protein.

Group V, claim(s) 78-81, drawn to DNA constructs and cells containing said constructs.

Group VI, claim(s) 82-96, drawn to methods of stimulating immune response using self-antigens.

Group VII, claim(s) 97-100, drawn to methods of stimulating immune response using ubiquitin fusion proteins.

Group VIII, claim(s) 101, drawn to method of stimulating immune response using DNA constructs.

Group IX, claim(s) 102, drawn to method of identifying antibodies.

Group X, claim(s) 103-109, drawn to methods of reducing levels of endogenous proteins using ubiquitin fusion proteins.

Group XI, claim(s) 110-116, drawn to methods of reducing levels of endogenous proteins using DNA constructs.

The inventions listed as Groups I-XI do not relate to a single general inventive concept under PCT Rule 13.1 because, under PCT Rule 13.2, they lack the same or corresponding special technical features for the following reasons:

Pursuant to 37 C.F.R. 1.475(d), the ISA/US considers that where multiple products and processes are claimed, the main invention shall consist of the first invention of the category first mentioned in the claims and the first recited invention of each of the other categories related thereto. Accordingly, the main invention (Group I) comprises the first-recited product, fusion proteins comprising a heat shock protein to a single epitope-containing segment. Further pursuant to 37 C.F.R. 1.475(d), the ISA/US considers that any feature which the subsequently recited products and methods share with the main invention does not constitute a special technical feature within the meaning of PCT rule 13.2 and that each of such products and methods accordingly defines a separate invention.